Breaking News Instant updates and real-time market news.

2020-10-29 09:51:49 CCXI ChemoCentryx $46.70 / -5.51 (-10.55%) , FSLR First Solar $92.08 / -1.24 (-1.33%) … 09:51 10/29/20 10/29 09:51 10/29/20 09:51	Fly Intel: Top five analyst downgrades Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ChemoCentryx (CCXI) downgraded to Neutral from Overweight at JPMorgan with analyst Anupam Rama saying he views the Phase 2 AURORA results for avacopan in hidradenitis suppurativa as "mixed." 2. First Solar (FSLR) downgraded to Neutral from Overweight at JPMorgan with analyst Paul Coster saying after rallying 67% year-to-date, the stock is now trading close to the price target and at "historically-elevated" multiples. 3. Exact Sciences (EXAS) downgraded to Neutral from Buy at UBS with analyst Dan Brennan saying the company's acquisition of Thrive is "strategically sound," but at current levels, the risk/reward on the stock is "more balanced." 4. C.H. Robinson (CHRW) downgraded to Equal Weight from Overweight at Stephens with analyst Jack Atkins saying he continues to view C.H. Robinson as a long-term winner as the third-party logistics industry consolidates, he prefers to move to the sidelines until there is greater visibility into the volume growth that he sees as necessary to drive revenue and profitability growth. 5. CAE (CAE) downgraded to Hold from Buy at Canaccord with analyst Doug Taylor citing valuation and a lack of visibility on growth reacceleration. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. CCXI ChemoCentryx $46.70 / -5.51 (-10.55%) FSLR First Solar $92.08 / -1.24 (-1.33%) EXAS Exact Sciences $128.00 / +0.33 (+0.26%) CHRW C.H. Robinson $89.40 / +0.82 (+0.93%) CAE CAE $16.85 / -0.25 (-1.46%)	10 Nov 17 Nov 07 Jul 11 Jun 17 Sep
CCXI FSLR EXAS CHRW CAE CCXI ChemoCentryx $46.70 / -5.51 (-10.55%) 10/29/20 SVB Leerink ChemoCentryx price target raised to $84 from $75 at SVB Leerink 10/29/20 Wells Fargo ChemoCentryx price target lowered to $70 from $79 at Wells Fargo 10/29/20 JPMorgan JPMorgan downgrades ChemoCentryx to Neutral after 'mixed' data 10/29/20 JPMorgan ChemoCentryx downgraded to Neutral from Overweight at JPMorgan FSLR First Solar $92.08 / -1.24 (-1.33%) 10/29/20 JPMorgan First Solar downgraded to Neutral after 67% rally at JPMorgan 10/29/20 JPMorgan First Solar downgraded to Neutral from Overweight at JPMorgan 10/28/20 Raymond James First Solar price target raised to $90 from $80 at Raymond James 10/28/20 Roth Capital First Solar price target raised to $110 from $100 at Roth Capital EXAS Exact Sciences $128.00 / +0.33 (+0.26%) 10/29/20 UBS Exact Sciences downgraded to Neutral from Buy at UBS 10/28/20 Fly Intel: Top five analyst downgrades 10/28/20 Benchmark Exact Sciences price target raised to $145 from $110 at Benchmark 10/28/20 SVB Leerink Exact Sciences price target raised to $160 from $115 at SVB Leerink CHRW C.H. Robinson $89.40 / +0.82 (+0.93%) 10/29/20 Wells Fargo C.H. Robinson price target lowered to $78 from $92 at Wells Fargo 10/29/20 Stephens C.H. Robinson downgraded to Equal Weight at Stephens 10/29/20 Stephens C.H. Robinson downgraded to Equal Weight from Overweight at Stephens 10/28/20 Morgan Stanley C.H. Robinson's next few quarters to be 'very challenging,' says Morgan Stanley CAE CAE $16.85 / -0.25 (-1.46%) 10/29/20 Canaccord CAE downgraded to Hold from Buy at Canaccord 09/30/20 BMO Capital CAE upgraded to Outperform from Market Perform at BMO Capital 08/14/20 TD Securities CAE price target raised to C$21 from C$20 at TD Securities 08/13/20 RBC Capital CAE price target lowered to C$27 from C$28 at RBC Capital

2020-10-29 09:51:49

CCXI

ChemoCentryx

$46.70 / -5.51 (-10.55%)

, FSLR

First Solar

$92.08 / -1.24 (-1.33%)

… 09:51

10/29/20

10/29

09:51

10/29/20

09:51

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ChemoCentryx (CCXI) downgraded to Neutral from Overweight at JPMorgan with analyst Anupam Rama saying he views the Phase 2 AURORA results for avacopan in hidradenitis suppurativa as "mixed." 2. First Solar (FSLR) downgraded to Neutral from Overweight at JPMorgan with analyst Paul Coster saying after rallying 67% year-to-date, the stock is now trading close to the price target and at "historically-elevated" multiples. 3. Exact Sciences (EXAS) downgraded to Neutral from Buy at UBS with analyst Dan Brennan saying the company's acquisition of Thrive is "strategically sound," but at current levels, the risk/reward on the stock is "more balanced." 4. C.H. Robinson (CHRW) downgraded to Equal Weight from Overweight at Stephens with analyst Jack Atkins saying he continues to view C.H. Robinson as a long-term winner as the third-party logistics industry consolidates, he prefers to move to the sidelines until there is greater visibility into the volume growth that he sees as necessary to drive revenue and profitability growth. 5. CAE (CAE) downgraded to Hold from Buy at Canaccord with analyst Doug Taylor citing valuation and a lack of visibility on growth reacceleration. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

CCXI

ChemoCentryx

$46.70 / -5.51 (-10.55%)

FSLR

First Solar

$92.08 / -1.24 (-1.33%)

EXAS

Exact Sciences

$128.00 / +0.33 (+0.26%)

CHRW

C.H. Robinson

$89.40 / +0.82 (+0.93%)

CAE

$16.85 / -0.25 (-1.46%)

10
Nov
17
Nov
07
Jul

11
Jun
17
Sep

CCXI
FSLR
EXAS
CHRW
CAE

CCXI ChemoCentryx

$46.70 / -5.51 (-10.55%)

10/29/20 SVB Leerink: ChemoCentryx price target raised to $84 from $75 at SVB Leerink

10/29/20 Wells Fargo: ChemoCentryx price target lowered to $70 from $79 at Wells Fargo

10/29/20 JPMorgan: JPMorgan downgrades ChemoCentryx to Neutral after 'mixed' data

10/29/20 JPMorgan: ChemoCentryx downgraded to Neutral from Overweight at JPMorgan

FSLR First Solar

$92.08 / -1.24 (-1.33%)

10/29/20 JPMorgan: First Solar downgraded to Neutral after 67% rally at JPMorgan

10/29/20 JPMorgan: First Solar downgraded to Neutral from Overweight at JPMorgan

10/28/20 Raymond James: First Solar price target raised to $90 from $80 at Raymond James

10/28/20 Roth Capital: First Solar price target raised to $110 from $100 at Roth Capital

EXAS Exact Sciences

$128.00 / +0.33 (+0.26%)

10/29/20 UBS: Exact Sciences downgraded to Neutral from Buy at UBS

10/28/20: Fly Intel: Top five analyst downgrades

10/28/20 Benchmark: Exact Sciences price target raised to $145 from $110 at Benchmark

10/28/20 SVB Leerink: Exact Sciences price target raised to $160 from $115 at SVB Leerink

CHRW C.H. Robinson

$89.40 / +0.82 (+0.93%)

10/29/20 Wells Fargo: C.H. Robinson price target lowered to $78 from $92 at Wells Fargo

10/29/20 Stephens: C.H. Robinson downgraded to Equal Weight at Stephens

10/29/20 Stephens: C.H. Robinson downgraded to Equal Weight from Overweight at Stephens

10/28/20 Morgan Stanley: C.H. Robinson's next few quarters to be 'very challenging,' says Morgan Stanley

CAE CAE

$16.85 / -0.25 (-1.46%)

10/29/20 Canaccord: CAE downgraded to Hold from Buy at Canaccord

09/30/20 BMO Capital: CAE upgraded to Outperform from Market Perform at BMO Capital

08/14/20 TD Securities: CAE price target raised to C$21 from C$20 at TD Securities

08/13/20 RBC Capital: CAE price target lowered to C$27 from C$28 at RBC Capital

TODAY'S FREE FLY STORIES

Conference/Events	JPMorgan leisure/broadlines analyst to hold analyst/industry conference call » 17:30 12/05/20 12/05 17:30 12/05/20 17:30 Leisure/Broadlines &… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Conference/Events	British American Tobacco to host conference call » 17:14 12/05/20 12/05 17:14 12/05/20 17:14 BTI British American Tobacco $36.94 / +0.4 (+1.09%) Management holds a full… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly BTI British American Tobacco $36.94 / +0.4 (+1.09%) 11/03/20 British American Tobacco acquires nicotine pouch product assets of Dryft 08/31/20 Lexaria Bioscience enters R&D agreement with British American Tobacco BTI British American Tobacco $36.94 / +0.4 (+1.09%) 09/22/20 Fly Intel: Top five analyst upgrades 09/22/20 RBC Capital British American Tobacco upgraded to Outperform at RBC Capital 09/22/20 RBC Capital British American upgraded to Outperform from Sector Perform at RBC Capital 09/02/20 Morgan Stanley British American Tobacco price target lowered to 3,330 GBp at Morgan Stanley BTI British American Tobacco $36.94 / +0.4 (+1.09%) 09/09/20 Youth vaping slips significantly in the U.S., WSJ reports 08/28/20 California lawmakers approve menthol cigarette ban, WSJ reports 08/28/20 California lawmakers approve menthol cigarette ban, WSJ reports 07/21/20 Puff Bar e-cigarettes banned by FDA, WSJ reports BTI British American Tobacco $36.94 / +0.4 (+1.09%) 08/28/20 Fly Intel: Wall Street's top stories for Friday
Conference/Events	Roche to hold a conference call » 17:09 12/05/20 12/05 17:09 12/05/20 17:09 RHHBY Roche $0.00 / + (+0.00%) Management discusses key… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 12/01/20 Blueprint Medicines announces FDA approval of Gavreto 12/01/20 Roche's Genentech announces FDA approval of Gavreto 12/01/20 Genentech receives FDA approval for Xolair for treatment of nasal polyps 12/01/20 Roche announces EUA for Elecsys Anti-SARS-CoV-2 S test RHHBY Roche $0.00 / + (+0.00%) 11/27/20 UBS Roche price target lowered to CHF 365 from CHF 370 at UBS 11/11/20 Truist Opthea initiated with a Buy at Truist 10/16/20 UBS Roche price target lowered to CHF 370 from CHF 390 at UBS 10/06/20 Goldman Sachs Goldman reiterates $34 target on Kiniksa after 'impressive' data RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS RHHBY Roche $0.00 / + (+0.00%) 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says 11/11/20 Roche's Franz favors COVID-19 vaccination mandate, Reuters says RHHBY Roche $0.00 / + (+0.00%) 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday 11/21/20 Week in review: How Trump's policies moved stocks 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 12/06/20 62nd Virtual Annual Meeting of ASH 12/10/20 San Antonio Breast Cancer Virtual Symposium
Conference/Events	Disney to host virtual investor day » 15:04 12/05/20 12/05 15:04 12/05/20 15:04 DIS Disney $154.16 / +0.95 (+0.62%) Virtual Investor Day to… Virtual Investor Day to be held on December 10 at 4:30 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options DIS Disney $154.16 / +0.95 (+0.62%) 11/26/20 Disney to lay off 32,000 parks employees in first half of 2021 11/23/20 Google, Disney partner over 'Mandalorian' AR experience 11/18/20 S&P cuts Disney credit ratings one notch with Negative outlook 11/16/20 Disney partners with chef Roy Choi to launch Mickey & Friends(giving) DIS Disney $154.16 / +0.95 (+0.62%) 12/02/20 Citi Disney price target raised to $175 from $150 at Citi 12/01/20 UBS Disney price target raised to $155 from $126 at UBS 11/13/20 Fly Intel: Top five analyst upgrades 11/13/20 JPMorgan Disney price target raised to $160 from $155 at JPMorgan DIS Disney $154.16 / +0.95 (+0.62%) 11/12/20 Disney sees FY21 results continuing to be affected by COVID-19 11/12/20 Disney reports Q4 EPS ex-items (20c), consensus (71c) 11/12/20 Notable companies reporting after market close 08/04/20 Disney sees FY20 CapEx roughly $700M lower than last year DIS Disney $154.16 / +0.95 (+0.62%) 12/02/20 Discovery to launch streaming service in January for $4.99 per month, CNBC says 12/02/20 Discovery partnering with Verizon on Discovery+ launch, CNBC says 12/01/20 Disney consolidates TV assets into two units, Reuters reports 11/20/20 Disney weighs Disney+ premieres for 'Cruella,' 'Pinocchio,' Deadline reports DIS Disney $154.16 / +0.95 (+0.62%) 11/24/20 Game On: KeyBanc concerned about lack of 'Call of Duty' sales data 11/13/20 Fly Intel: Wall Street's top stories for Friday 11/13/20 Fly Intel: Wall Street's top stories at midday 11/13/20 Disney upgrade among today's top calls on Wall Street 12/10/20 The Walt Disney Company DIS Disney $154.16 / +0.95 (+0.62%) 11/13/20 Notable open interest changes for November 13th 10/13/20 Early notable gainers among liquid option names on October 13th 10/13/20 Unusually active option classes on open October 13th 09/03/20 Disney call volume above normal and directionally bullish
Conference/Events	Compass Diversified to host Virtual Investor Day » 15:00 12/05/20 12/05 15:00 12/05/20 15:00 CODI Compass Diversified $20.24 / +0.39 (+1.96%) Virtual Investor Day to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events CODI Compass Diversified $20.24 / +0.39 (+1.96%) 10/19/20 Compass Diversified completes acquisition of BOA Technology 10/02/20 Compass Diversified announces Sterno Group CEO Don Hinshaw to retire 09/22/20 Compass Diversified to acquire BOA Technology for $454M 09/14/20 Compass Diversified appoints Katie Melzer as head of business development CODI Compass Diversified $20.24 / +0.39 (+1.96%) 07/28/20 Roth Capital Compass Diversified assumed with a Buy at Roth Capital 04/22/20 Jefferies Compass Diversified resumed with a Buy at Jefferies CODI Compass Diversified $20.24 / +0.39 (+1.96%) 10/28/20 Compass Diversified reports Q3 EPS 8c, consensus 27c 07/29/20 Compass Diversified sees continued negative impact from COVID-19 in second half 07/29/20 Compass Diversified reports Q2 EPS (30c), consensus 6c 05 May 12/10/20 Deer Valley Virtual Consumer Event 12/11/20 Outdoor Lifestyles: What to Expect for the Rest of the Pandemic 12/10/20 Compass Diversified Holdings

Conference/Events	Edwards Lifesciences to host virtual investor meeting » 14:58 12/05/20 12/05 14:58 12/05/20 14:58 EW Edwards Lifesciences $85.76 / +2.255 (+2.70%) Virtual Investor Meeting… Virtual Investor Meeting to be held on December 10 at 12 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options EW Edwards Lifesciences $85.76 / +2.255 (+2.70%) 07/23/20 Edwards Lifesciences jumps 6% after Q2 results beat ests, FY20 guidance raised 07/15/20 Edwards Lifesciences' Konect Resilia approved by FDA for aortic valve surgery 07/15/20 Edwards Lifesciences appoints Paul LaViolette to board 07/13/20 Edwards Lifesciences settles outstanding patent disputes with Abbott EW Edwards Lifesciences $85.76 / +2.255 (+2.70%) 11/18/20 Wells Fargo Medtronic price target raised to $127 from $118 at Wells Fargo 11/17/20 Piper Sandler Boston Scientific recall 'positive' for Edwards, Medtronic, says Piper Sandler 10/27/20 Jefferies Edwards Lifesciences price target raised to $105 from $95 at Jefferies 10/22/20 Credit Suisse Edwards Lifesciences price target raised to $97 from $92 at Credit Suisse EW Edwards Lifesciences $85.76 / +2.255 (+2.70%) 10/21/20 Edwards Lifesciences sees Q4 underlying sales growth 'similar' to Q3 10/21/20 Edwards Lifesciences raises FY20 adj. EPS view to $1.85-$1.95 from $1.75-$1.95 10/21/20 Edwards Lifesciences reports Q3 adjusted EPS 51c, consensus 44c 10/21/20 Notable companies reporting after market close EW Edwards Lifesciences $85.76 / +2.255 (+2.70%) 10/21/20 Fly Intel: After-Hours Movers 07/23/20 Fly Intel: After-Hours Movers 07/13/20 Fly Intel: After-Hours Movers 12/10/20 Edwards Lifesciences Corp. EW Edwards Lifesciences $85.76 / +2.255 (+2.70%) 11/17/20 Early notable gainers among liquid option names on November 17th
Conference/Events	MKS Instruments to host virtual analyst day » 14:56 12/05/20 12/05 14:56 12/05/20 14:56 MKSI MKS Instruments $151.67 / +8.61 (+6.02%) Virtual Analyst Day to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events MKSI MKS Instruments $151.67 / +8.61 (+6.02%) 12/02/20 MKS Instruments seeing 'strong' sales for flexible PCB laser processing solution 09/02/20 MKS Instruments announces purchase of multiple ESI Geode systems 06/21/20 Fly Intel: Top five weekend stock stories MKSI MKS Instruments $151.67 / +8.61 (+6.02%) 12/01/20 Stifel Micron's Q1 preannouncement supports recent Stifel channel checks 10/14/20 Stifel Stifel remains bullish on MKS, highlights exposure to flexible PCB market 09/11/20 Berenberg MKS Instruments initiated with a Buy at Berenberg 07/31/20 Deutsche Bank MKS Instruments price target raised to $145 from $130 at Deutsche Bank MKSI MKS Instruments $151.67 / +8.61 (+6.02%) 10/27/20 MKS Instruments sees Q4 EPS $2.00, +/- 20c, consensus $1.68 10/27/20 MKS Instruments reports Q3 EPS $1.93, consensus $1.77 07/29/20 MKS Instruments sees Q3 EPS $1.55-$1.95, consensus $1.13 07/29/20 MKS Instruments reports Q2 EPS $1.62, consensus $1.18 MKSI MKS Instruments $151.67 / +8.61 (+6.02%) 06/20/20 Intel, Western Digital among cheap tech stops, Barron's says MKSI MKS Instruments $151.67 / +8.61 (+6.02%) 10/27/20 Fly Intel: After-Hours Movers 07/29/20 Fly Intel: After-Hours Movers 12/10/20 MKS Instruments
Conference/Events	Netgear to host virtual analyst day » 14:54 12/05/20 12/05 14:54 12/05/20 14:54 NTGR Netgear $34.17 / +0.46 (+1.36%) Virtual Analyst Day to be… Virtual Analyst Day to be held on December 10 at 11 am. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NTGR Netgear $34.17 / +0.46 (+1.36%) 10/21/20 Netgear to maintain suspended Q4 guidance NTGR Netgear $34.17 / +0.46 (+1.36%) 10/22/20 Cowen Netgear price target raised to $43 from $35 at Cowen 10/22/20 Deutsche Bank Netgear price target raised to $39 from $32 at Deutsche Bank 07/23/20 BWS Financial Netgear price target raised to $45 from $33 at BWS Financial 07/23/20 Deutsche Bank Netgear price target raised to $32 from $25 at Deutsche Bank NTGR Netgear $34.17 / +0.46 (+1.36%) 10/21/20 Netgear reports Q3 adjusted EPS $1.13, consensus 66c 07/22/20 Netgear continuing suspension of Q3, FY20 guidance 07/22/20 Netgear reports Q2 adjusted EPS 54c, consensus 22c NTGR Netgear $34.17 / +0.46 (+1.36%) 10/21/20 Fly Intel: After-Hours Movers 07/22/20 Fly Intel: After-Hours Movers 12/14/20 7th Annual Networking Virtual Summit 12/10/20 NETGEAR, Inc.
Conference/Events	Mosaic to host virtual analyst presentation » 14:50 12/05/20 12/05 14:50 12/05/20 14:50 MOS Mosaic $22.77 / +1.56 (+7.36%) Analyst Presentation III… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options MOS Mosaic $22.77 / +1.56 (+7.36%) 11/24/20 Mosaic reports Commerce's preliminary countervailing duty determinations 11/24/20 Commerce reports 'affirmative preliminary determinations' in Mosaic CVD case 11/16/20 Mosaic announces October potash sales revenue and volumes 11/03/20 Mosaic falls -14.0% MOS Mosaic $22.77 / +1.56 (+7.36%) 11/25/20 VTB Capital Mosaic downgraded to Sell from Hold at VTB Capital 11/24/20 Bernstein Commerce rules in Mosaic's favor on CVD complaint, says Bernstein 11/03/20 Scotiabank Mosaic downgraded to Sector Perform from Outperform at Scotiabank 10/21/20 Citi Mosaic downgraded to Neutral from Buy at Citi MOS Mosaic $22.77 / +1.56 (+7.36%) 11/02/20 Mosaic reports Q3 EPS 23c, consensus 17c 11/02/20 Notable companies reporting after market close 08/03/20 Mosaic reports Q2 adj. EPS 11c, consensus (1c) 08/03/20 Notable companies reporting after market close MOS Mosaic $22.77 / +1.56 (+7.36%) 11/03/20 Fly Intel: Wall Street's top stories for Tuesday 11/03/20 Fly Intel: Wall Street's top stories at midday 11/03/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: After-Hours Movers 12/10/20 The Mosaic Company MOS Mosaic $22.77 / +1.56 (+7.36%) 11/17/20 Unusually active option classes on open November 17th 11/16/20 Mosaic put volume heavy and directionally bearish 11/11/20 Mosaic put volume heavy and directionally bearish 09/23/20 Early notable gainers among liquid option names on September 23rd
Conference/Events	Astec to host virtual investor day » 14:23 12/05/20 12/05 14:23 12/05/20 14:23 ASTE Astec $62.38 / +2.92 (+4.91%) Virtual Investor Day to… Virtual Investor Day to be held on December 10 at 9 am. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Events ASTE Astec $62.38 / +2.92 (+4.91%) 11/04/20 Astec reports headcount reduction of approx. 12% since 3Q19 08/03/20 Astec acquires Concrete Equipment Company, BMH Systems, terms not disclosed ASTE Astec $62.38 / +2.92 (+4.91%) 04/23/20 Sidoti Astec downgraded to Neutral with $41 price target at Sidoti 04/23/20 Sidoti Astec downgraded to Neutral from Buy at Sidoti 04/01/20 Baird Astec upgraded to Outperform at Baird 04/01/20 Baird Astec upgraded to Outperform from Neutral at Baird ASTE Astec $62.38 / +2.92 (+4.91%) 11/04/20 Astec reports Q3 adj. EPS 20c, consensus 11c 08/05/20 Astec reports Q2 adj. EPS 67c, consensus 5c 12/10/20 Astec Industries, Inc.

Conference/Events	Broadridge to host virtual investor meeting » 14:22 12/05/20 12/05 14:22 12/05/20 14:22 BR Broadridge $149.20 / +1.26 (+0.85%) Virtual Investor Day to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events BR Broadridge $149.20 / +1.26 (+0.85%) 11/09/20 Broadridge names Edmund Reese as CFO, effective November 30 11/02/20 LiquidX announces multi-year investment from Broadridge 10/30/20 Broadridge narrows FY21 adjusted EPS view to 6%-10% from 4%-10% 10/13/20 Broadridge selected by Britannia Global for post-trade securities options BR Broadridge $149.20 / +1.26 (+0.85%) 08/17/20 JPMorgan Broadridge price target raised to $152 from $142 at JPMorgan 08/12/20 Fly Intel: Top five analyst downgrades 08/11/20 BTIG Broadridge downgraded to Neutral from Buy at BTIG 08/11/20 BTIG Broadridge downgraded to Neutral from Buy at BTIG BR Broadridge $149.20 / +1.26 (+0.85%) 10/30/20 Broadridge reports Q1 adjusted EPS 98c, consensus 63c 08/11/20 Broadridge sees FY21 adjusted EPS growth 4%10%, consensus $5.44 08/11/20 Broadridge reports Q4 adjusted EPS $2.15, consensus $2.09 12/10/20 Broadridge Financial Solutions Inc.
Conference/Events	Medicenna Therapeutics to hold a conference call » 14:11 12/05/20 12/05 14:11 12/05/20 14:11 MDNA Medicenna Therapeutics $3.87 / -0.11 (-2.76%) Management holds a Key… Management holds a Key Opinion Leader conference call to discuss MDNA55 for treatment of recurrent Glioblastoma Multiforme (rGBM) to be held on December 11 at 11 am. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings On The Fly MDNA Medicenna Therapeutics $3.87 / -0.11 (-2.76%) 11/18/20 Medicenna Therapeutics announces upcoming oral presentations at SNO meeting 11/13/20 Medicenna Therapeutics expects cash to be sufficient to mid-2022 11/13/20 Medicenna Therapeutics announces upcoming milestones 10/26/20 Medicenna Therapeutics presents preclinical data on IL-2, IL-13 Superkines MDNA Medicenna Therapeutics $3.87 / -0.11 (-2.76%) 09/10/20 H.C. Wainwright Medicenna Therapeutics initiated with a Buy at H.C. Wainwright MDNA Medicenna Therapeutics $3.87 / -0.11 (-2.76%) 11/13/20 Medicenna Therapeutics reports Q2 EPS (8c) vs (7c) last year. MDNA Medicenna Therapeutics $3.87 / -0.11 (-2.76%) 10/15/20 Fly Intel: After-Hours Movers
Conference/Events	American Society of Hematology (ASH) to hold a virtual meeting » 13:56 12/05/20 12/05 13:56 12/05/20 13:56 SDGR Schrodinger $66.08 / +1.34 (+2.07%) , TRIL Trillium Therapeutics $17.06 / -0.97 (-5.38%) , FRLN Freeline $16.47 / +0.25 (+1.54%) , SNDX Syndax $24.59 / +0.5 (+2.08%) , ADAP Adaptimmune $4.46 / -0.04 (-0.89%) , NEO NeoGenomics $48.00 / +0.13 (+0.27%) , MOR MorphoSys $28.40 / +0.22 (+0.78%) , MNTA Bought by JNJ $52.49 / + (+0.00%) , SNY Sanofi $51.01 / +0.97 (+1.94%) , REGN Regeneron $492.10 / -6.61 (-1.33%) , SGEN Seagen $179.37 / -0.625 (-0.35%) , RCKT Rocket Pharmaceuticals $32.02 / -1.78 (-5.27%) , VRTX Vertex Pharmaceuticals $228.24 / +1.58 (+0.70%) , PFE Pfizer $40.36 / +0.26 (+0.65%) , KDMN Kadmon $4.17 / +0.1 (+2.46%) , KPTI Karyopharm $16.26 / -0.38 (-2.28%) , GILD Gilead $61.57 / +0.7 (+1.15%) , KURA Kura Oncology $36.79 / +2.78 (+8.17%) , JAZZ Jazz Pharmaceuticals $150.58 / -0.4 (-0.26%) , JNJ Johnson & Johnson $150.30 / +1.35 (+0.91%) , NVS Novartis $91.58 / +1.35 (+1.50%) , NVO Novo Nordisk $67.82 / +0.62 (+0.92%) , FMTX Forma Therapeutics $43.53 / -0.26 (-0.59%) , AZN AstraZeneca $53.71 / +0.93 (+1.76%) , EPZM Epizyme $13.06 / +0.04 (+0.31%) , FATE Fate Therapeutics $60.68 / +0.29 (+0.48%) , DNA Bought by RHHBY $0.00 / + (+0.00%) , CRSP Crispr Therapeutics $147.30 / +6.74 (+4.80%) , BMRN BioMarin $79.62 / +0.53 (+0.67%) , BLUE Bluebird Bio $46.91 / -0.13 (-0.28%) , BGNE BeiGene $222.79 / +1.61 (+0.73%) , BAYRY Bayer $0.00 / + (+0.00%) , ALLO Allogene Therapeutics $33.56 / +1.27 (+3.93%) , AMGN Amgen $229.13 / +2.23 (+0.98%) 62nd Virtual Annual… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VRTX TRIL SNY SNDX SGEN SDGR REGN RCKT PFE NVS NVO NEO MOR MNTA KURA KPTI KDMN JNJ JAZZ GILD FRLN FMTX FATE EPZM CRSP BMRN BLUE BGNE BAYRY AZN AMGN ALLO ADAP VRTX Vertex Pharmaceuticals $228.24 / +1.58 (+0.70%) 12/01/20 Adicet Bio appoints Bastiano Sanna to board of directors 11/27/20 Vertex Pharmaceuticals: EC approves label extension of SYMKEVI with KALYDECO 11/20/20 Cytokinetics names Nancy Wysenski to board of directors 11/17/20 Imara appoints Lynette Hopkinson as SVP, regulatory TRIL Trillium Therapeutics $17.06 / -0.97 (-5.38%) 11/16/20 Trillium Therapeutics reports Q3 EPS (58c), consensus (90c) 11/02/20 Trillium Therapeutics appoints Ingmar Bruns M.D as Chief Medical Officer 11/02/20 Trillium Therapeutics announced the formation of a Scientific Advisory Board 10/05/20 Trillium Therapeutics receives notice of allowance for two patent applications SNY Sanofi $51.01 / +0.97 (+1.94%) 11/30/20 Sanofi, Kiadis Pharma provide update on acquisition offer 11/30/20 Regeneron, Sanofi announce EC extension of Dupixent marketing authorization 11/23/20 Sanofi reports European Commission approves MenQuadfi 11/20/20 Trump to sign orders in effort to cut prescription drug prices SNDX Syndax $24.59 / +0.5 (+2.08%) 11/02/20 Syndax CEO says making 'exciting progress' in Phase 1 of AUGMENT-101 trial 11/02/20 Syndax sees Q4 R&D expenses $15M-$20M 07/07/20 Syndax appoints Daphne Karydas as CFO SGEN Seagen $179.37 / -0.625 (-0.35%) 10/12/20 Astellas Pharma, Seagen announce results from second cohort of EV-201 trial 10/12/20 Seagen, Astellas announce positive topline results from Phase 2 EV-201 trial 10/08/20 Seattle Genetics changes corporate name to Seagen 09/21/20 Seattle Genetics, Genmab presents data from innovaTV 204 phase 2 trial SDGR Schrodinger $66.08 / +1.34 (+2.07%) 11/23/20 Schrodinger jumps 7% to $64.90 after announcing collaboration with Bristol-Myers 11/23/20 Schrodinger announces discovery collaboration with Bristol-Myers 11/13/20 Schrodinger holder David Shaw sells 547.3K shares of common stock 09/24/20 Schrodinger director institutional holder DE Shaw sells 454K shares REGN Regeneron $492.10 / -6.61 (-1.33%) 11/23/20 Kiniksa announces FDA acceptance of sBLA, priority review for rilonacept 11/22/20 Fly Intel: Top five weekend stock stories 11/22/20 Regeneron receives Emergency Use Authorization for Covid antibody cocktail RCKT Rocket Pharmaceuticals $32.02 / -1.78 (-5.27%) 11/13/20 Rocket Pharmaceuticals receives $3.7M in funding from CIRM for RP-L401 trial 10/16/20 Rocket Pharmaceuticals presents preliminary RP-L201 study data at ESID meeting 09/02/20 Rocket announces first patient treated in higher dose cohort of RP-A501 trial 08/27/20 Rocket Pharmaceuticals receives FDA Fast Track Designation for RP-L401 for IMO PFE Pfizer $40.36 / +0.26 (+0.65%) 12/02/20 Health Canada sees Pfizer/BioNTech vaccine review to be completed soon 12/02/20 Mexico to buy 34.4M doses of COVID-19 vaccine from Pfizer 12/02/20 NY Governor says first delivery of Pfizer vaccine in state expected December 15 12/02/20 Pfizer, BioNTech COVID-19 vaccine receives authorization for emergency use in UK NVS Novartis $91.58 / +1.35 (+1.50%) 12/04/20 Novartis announces REACH3 trial of Jakavi reaches primary endpoint 12/04/20 Incyte: Jakafi improved outcomes in patients in REACH3 trial 11/24/20 Novartis initiating share buyback of up to $2.5B NVO Novo Nordisk $67.82 / +0.62 (+0.92%) 12/04/20 Novo Nordisk files for U.S. FDA regulatory approval of once-weekly semaglutide 11/17/20 Novo Nordisk reports SUSTAIN FORTE trial achieved primary endpoint 11/16/20 Aeterna Zentaris amends license agreement with Novo Nordisk 11/15/20 Gilead, Novo Nordisk present new data from Proof-of-Concept trial in NASH NEO NeoGenomics $48.00 / +0.13 (+0.27%) 11/18/20 NeoGenomics' Hipp sells 70,000 common shares 10/13/20 NeoGenomics to expand global footprint in pharma services 06/29/20 NeoGenomics commercially launches InVisionFirst-Lung in the U.S. MOR MorphoSys $28.40 / +0.22 (+0.78%) 12/02/20 MorphoSys says Janssen reports European Commission approval for Tremfya 11/11/20 Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo 11/04/20 MorphoSys to present Tafasitamab data at ASH Virtual Annual Meeting 09/30/20 MorphoSys CFO Holstein to step down effective December 31, 2020 MNTA Bought by JNJ $52.49 / + (+0.00%) 10/01/20 Momenta completes proposed sale to Johnson & Johnson 10/01/20 Johnson & Johnson completes acquisition of Momenta 10/01/20 Chesapeake Utilities to replace Momenta in S&P 600 at open on 10/1 KURA Kura Oncology $36.79 / +2.78 (+8.17%) 11/05/20 Kura Oncology expects cash to fund operations into 2023 11/04/20 Kura Oncology says abstract with preliminary data from KOMET-001 trial posted 10/26/20 Kura Oncology reports preclinical data showing antitumor activity of tipifarnib 08/25/20 Kura Oncology appoints Stephen Dale as CMO KPTI Karyopharm $16.26 / -0.38 (-2.28%) 12/01/20 Karyopharm announces leadership appointments 11/25/20 Karyopharm's ongoing Xpovio Phase 3 trial to proceed as planned 11/20/20 Karyopharm reports 'positive' Phase 3 SEAL data in oral presentation 11/12/20 Karyopharm says Phase 3 BOSTON study results published in The Lancet KDMN Kadmon $4.17 / +0.1 (+2.46%) 11/30/20 Kadmon announces FDA acceptance of belumosudil NDA 10/13/20 Kadmon to transfer U.S. stock exchange listing to Nasdaq 09/30/20 Kadmon submits Belumosudil NDA to FDA 09/08/20 Kadmon granted ODD from FDA for belumosudil JNJ Johnson & Johnson $150.30 / +1.35 (+0.91%) 12/03/20 Johnson & Johnson names Dr. Nadja West to Board of Directors 12/03/20 Janssen submits amivantamab BLA to FDA JAZZ Jazz Pharmaceuticals $150.58 / -0.4 (-0.26%) 12/03/20 Jazz Pharmaceuticals announces ATLANTIS study did not meet primary endpoint 11/02/20 Jazz Pharmaceuticals jumps 8% to $159 after Q3 earnings beat 10/26/20 Jazz Pharmaceuticals acquires SpringWorks Therapeutics' FAAH inhibitor program 10/20/20 Jazz Pharma announces results of Phase 3 study of Xywav oral solution GILD Gilead $61.57 / +0.7 (+1.15%) 11/25/20 FDA says approval of remdesivir met 'legal and scientific standard' 11/19/20 WHO panel advises against use of Gilead's remdesivir for COVID-19 11/19/20 Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination 11/19/20 FDA issues EUA for Eli Lilly's baricitinib in combination with remdesivir FRLN Freeline $16.47 / +0.25 (+1.54%) 11/02/20 Freeline appoints Mark Baldry as CCO 09/28/20 Freeline promotes Romuald Corbau as CSO 09/23/20 Freeline announces supply agreement for haemophilia B program 08/14/20 Citi appointed as depositary bank for Freeline ADR programme FMTX Forma Therapeutics $43.53 / -0.26 (-0.59%) 11/10/20 Forma Therapeutics FT-4202 gets orphan drug designation in Europe 10/26/20 Forma Tpresents data from a planned interim analysis of olutasidenib, FATE Fate Therapeutics $60.68 / +0.29 (+0.48%) 12/04/20 Fate Therapeutics reports 'positive' ph1 trial data for FT516 in B-cell lymphoma 11/16/20 Fate Therapeutics director sells 25K shares of common stock 08/19/20 Fate Therapeutics appoints Edward Dulac as CFO 08/12/20 Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant EPZM Epizyme $13.06 / +0.04 (+0.31%) 11/06/20 Epizyme sees funds sufficient into at least 2023 10/07/20 Epizyme's Tazverik Phase 2 data featured in two Lancet Oncology publications 06/18/20 Epizyme receives accelerated approval for Tazverik for two FL indications CRSP Crispr Therapeutics $147.30 / +6.74 (+4.80%) 10/28/20 Crispr to initiate Phase 1/2 trial of stem cell-derived therapy in 2021 10/28/20 Crispr Therapeutics expects to report data from Phase 1 trials of CTX130 in 2021 10/28/20 Crispr Therapeutics expects to report data from Phase 1 trial of CTX120 in 2021 10/28/20 Crispr Therapeutics to report additional data from Phase 1 CARBON trial in 2021 BMRN BioMarin $79.62 / +0.53 (+0.67%) 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies 11/05/20 BioMarin confident in valoctocogene roxaparvovec gene therapy 11/02/20 FDA accepts BioMarin's NDA for Vosoritide to treat children with Achondroplasia BLUE Bluebird Bio $46.91 / -0.13 (-0.28%) 12/04/20 Magenta, Bluebird announce exclusive clinical trial collaboration for MGTA-145 11/05/20 Bluebird Bio pushes back sickle cell submission timing to late 2022 10/02/20 Bluebird Bio announces EMA acceptance of elivaldogene autotemcel MAA 10/01/20 Akouos appoints Sachiyo Minegishi as CFO, Jennifer Wellman to COO BGNE BeiGene $222.79 / +1.61 (+0.73%) 11/19/20 BeiGene's XGEVA approved in China for prevention of SREs in solid tumors and MM 11/05/20 BeiGene CFO Liang to retire 10/06/20 BioAtla and BeiGene revise development and commercialization pact for BA3071 09/30/20 BeiGene CEO sells 54.3K shares of common stock BAYRY Bayer $0.00 / + (+0.00%) 11/23/20 Argenx to acquire FDA PRV from Bayer for $98M 11/09/20 Editas Medicine appoints Lisa Michaels as CMO 10/27/20 Bayer signs LOI to build new distribution center in Saxonburg, PA 10/26/20 Bayer acquires AskBio for $2B consideration upfront, $2B in potential milestones AZN AstraZeneca $53.71 / +0.93 (+1.76%) 12/02/20 FibroGen to present Roxadustat Phase 3 analyses at ASH meeting 12/01/20 AstraZeneca reports Crestor to be divested to Grunenthal in Europe 11/30/20 Genprex initiates site recruitment for Acclaim-1 clinical trial 11/30/20 AstraZeneca reports Forxiga approved in Japan for chronic heart failure AMGN Amgen $229.13 / +2.23 (+0.98%) 12/04/20 McKesson, Amgen sign strategic agreement to help improve cancer care 11/23/20 Cytokinetics regains rights to develop omecamtiv mecarbil, AMG 594 11/23/20 Amgen to transition development rights for omecamtiv mecarbil, AMG 594 11/10/20 AstraZeneca, Amgen study for severe asthma meets primary endpoint ALLO Allogene Therapeutics $33.56 / +1.27 (+3.93%) 11/04/20 Allogene announces presentation of results from Phase 1 study of ALLO-715 11/04/20 Allogene Therapeutics expects to initiate cGMP manufacturing in 2021 11/04/20 Allogene Therapeutics expects IND to be submitted for ALLO-316 by year-end 11/04/20 Allogene Therapeutics expects initiation of Phase 2 trial of ALLO-501 in 2021 ADAP Adaptimmune $4.46 / -0.04 (-0.89%) 11/20/20 Adaptimmune sees current cash runway into early 2023 11/20/20 Adaptimmune to showcase market potential for SPEAR T-cell portfolio, pipeline 11/19/20 Adaptimmune presents durability of response data from Phase 1 ADP-A2M4 trial 11/09/20 Adaptimmune says SURPASS data support continued development of ADP-A2M4CD8 SDGR TRIL FRLN SNDX ADAP NEO MOR MNTA SNY REGN SGEN RCKT VRTX PFE KDMN KPTI GILD KURA JAZZ JNJ NVS NVO FMTX AZN EPZM FATE DNA CRSP BMRN BLUE BGNE BAYRY ALLO AMGN SDGR Schrodinger $66.08 / +1.34 (+2.07%) 11/23/20 BofA BofA upgrades Schrodinger to Buy after 'major' collaboration announcement 11/23/20 BofA Schrodinger upgraded to Buy from Neutral at BofA 10/12/20 Jefferies Schrodinger upgraded to Buy from Hold at Jefferies 08/10/20 Schrodinger files to sell 4.5M shares of common stock TRIL Trillium Therapeutics $17.06 / -0.97 (-5.38%) 11/18/20 Craig-Hallum Trillium Therapeutics price target raised to $21 from $15 at Craig-Hallum 11/04/20 Cowen Trillium ASH abstracts provide 'minimal updates', says Cowen 10/12/20 Evercore ISI Trillium Therapeutics initiated with an Outperform at Evercore ISI 10/05/20 Piper Sandler Patent fight likely to weigh on ALX Oncology shares NT, says Piper Sandler FRLN Freeline $16.47 / +0.25 (+1.54%) 11/25/20 Redburn Freeline initiated with a Neutral at Redburn 09/01/20 Evercore ISI Freeline initiated with an Outperform at Evercore ISI 09/01/20 Wedbush Wedbush bullish on Freeline, initiates with an Outperform 09/01/20 Wedbush Freeline initiated with an Outperform at Wedbush SNDX Syndax $24.59 / +0.5 (+2.08%) 12/02/20 Stifel Syndax initiated with a Buy at Stifel 11/19/20 Barclays Syndax price target raised to $29 from $23 at Barclays 05/22/20 H.C. Wainwright Syndax downgraded to Neutral from Buy at H.C. Wainwright 05/22/20 H.C. Wainwright Syndax downgraded to Neutral from Buy at H.C. Wainwright ADAP Adaptimmune $4.46 / -0.04 (-0.89%) 08/12/20 Piper Sandler TCR2 Therapeutics initiated with an Overweight at Piper Sandler 06/01/20 Mizuho Adaptimmune price target raised to $9 from $3 at Mizuho 05/29/20 JonesTrading JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern' 05/29/20 JonesTrading Adaptimmune upgraded to Buy from Hold at JonesTrading NEO NeoGenomics $48.00 / +0.13 (+0.27%) 11/20/20 SVB Leerink NeoGenomics price target raised to $50 from $47 at SVB Leerink 10/28/20 Needham NeoGenomics price target raised to $46 from $39 at Needham 10/28/20 Craig-Hallum NeoGenomics price target raised to $50 from $42 at Craig-Hallum 09/09/20 Morgan Stanley NeoGenomics initiated with an Overweight at Morgan Stanley MOR MorphoSys $28.40 / +0.22 (+0.78%) 11/25/20 Fly Intel: Top five analyst initiations 11/25/20 Morgan Stanley MorphoSys initiated with an Equal Weight at Morgan Stanley 11/18/20 Goldman Sachs MorphoSys initiated with a Neutral at Goldman Sachs 11/13/20 Barclays MorphoSys price target lowered to EUR 90 from EUR 110 at Barclays MNTA Bought by JNJ $52.49 / + (+0.00%) 08/25/20 Baird Immunovant price target raised to $47 from $31 at Baird 08/25/20 Chardan Immunovant price target raised to $45 from $35 at Chardan 08/25/20 H.C. Wainwright Momenta downgraded to Neutral from Buy at H.C. Wainwright 08/24/20 Raymond James Momenta initiated with a Market Perform at Raymond James SNY Sanofi $51.01 / +0.97 (+1.94%) 11/30/20 Morgan Stanley AbbVie price target raised to $120 from $108 at Morgan Stanley 11/03/20 Morgan Stanley Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley 10/30/20 JPMorgan Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan 10/06/20 Raymond James Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov. REGN Regeneron $492.10 / -6.61 (-1.33%) 11/23/20 Piper Sandler Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler 11/11/20 Truist Opthea initiated with a Buy at Truist 11/10/20 SVB Leerink Regeneron price target lowered to $643 from $653 at SVB Leerink SGEN Seagen $179.37 / -0.625 (-0.35%) 10/13/20 JMP Securities Seagen price target raised to $216 from $200 at JMP Securities 09/22/20 Stifel Seattle Genetics price target raised to $165 from $145 at Stifel 09/22/20 JMP Securities Seattle Genetics price target raised to $200 from $185 at JMP Securities 09/21/20 Piper Sandler Tisotumab data sets Seattle Genetics up for another approval, says Piper Sandler RCKT Rocket Pharmaceuticals $32.02 / -1.78 (-5.27%) 11/23/20 JPMorgan Rocket Pharmaceuticals price target raised to $43 from $38 at JPMorgan 10/16/20 Chardan Rocket update illustrates optimized manufacturing, says Chardan 10/16/20 Piper Sandler Piper Sandler 'encouraged' by Rocket Pharmaceuticals' ESID updates 09/22/20 Oppenheimer Rocket Pharmaceuticals price target lowered to $33 from $43 at Oppenheimer VRTX Vertex Pharmaceuticals $228.24 / +1.58 (+0.70%) 11/30/20 RBC Capital Vertex Pharmaceuticals upgraded to Outperform from Sector Perform at RBC Capital 11/30/20 RBC Capital Vertex upgraded to Outperform from Sector Perform at RBC Capital 11/20/20 Fly Intel: Top five analyst initiations 11/20/20 Bernstein Vertex Pharmaceuticals initiated with an Outperform at Bernstein PFE Pfizer $40.36 / +0.26 (+0.65%) 12/04/20 Barclays Pfizer price target raised to $37 from $35 at Barclays 12/01/20 Morgan Stanley COVID mRNA vaccines seen with vast majority of U.S. market, says Morgan Stanley 11/30/20 BofA BofA downgrades BioNTech to Neutral with 'best in class' vaccine seen priced in 11/27/20 Argus AstraZeneca's COVID vaccine faces high bar for FDA authorization, says Argus KDMN Kadmon $4.17 / +0.1 (+2.46%) 11/11/20 Fly Intel: Top five analyst initiations 11/11/20 Mizuho Kadmon initiated with a Buy, $13 price target at Mizuho 11/10/20 Mizuho Kadmon initiated with a Buy at Mizuho 08/17/20 Loeb's Third Point buys Alibaba, makes a top holding, during second quarter KPTI Karyopharm $16.26 / -0.38 (-2.28%) 09/25/20 RBC Capital Karyopharm shares undervalued as seli moves into MF, says RBC Capital 07/01/20 Morgan Stanley Karyopharm initiated with an Overweight at Morgan Stanley 06/23/20 JPMorgan Karyopharm price target raised to $37 from $31 at JPMorgan 06/23/20 RBC Capital Karyopharm price target raised to $30 from $28 at RBC Capital GILD Gilead $61.57 / +0.7 (+1.15%) 11/24/20 Evercore ISI Atea Pharmaceuticals initiated with an Outperform at Evercore ISI 11/24/20 Berenberg Arcus Biosciences initiated with a Buy at Berenberg 11/20/20 Raymond James Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James 11/03/20 Fly Intel: Top five analyst initiations KURA Kura Oncology $36.79 / +2.78 (+8.17%) 12/02/20 Stifel Kura Oncology initiated with a Buy at Stifel 11/05/20 Piper Sandler Piper downgrades Kura Oncology to Neutral with KO-539 expectations priced in 11/05/20 Piper Sandler Kura Oncology downgraded to Neutral from Overweight at Piper Sandler 10/26/20 JMP Securities Kura Oncology price target raised to $33 from $22 at JMP Securities JAZZ Jazz Pharmaceuticals $150.58 / -0.4 (-0.26%) 11/03/20 SVB Leerink Jazz Pharmaceuticals price target raised to $202 from $194 at SVB Leerink 11/03/20 Wells Fargo Jazz Pharmaceuticals price target raised to $184 from $171 at Wells Fargo 11/03/20 RBC Capital Jazz Pharmaceuticals price target raised to $180 from $170 at RBC Capital 11/03/20 Barclays Jazz Pharmaceuticals price target raised to $233 from $225 at Barclays JNJ Johnson & Johnson $150.30 / +1.35 (+0.91%) 11/24/20 Raymond James Intuitive Surgical not surprised by J&J robot features, says Raymond James 11/23/20 SVB Leerink AstraZeneca vaccine 'will never be licensed in the U.S.,' says SVB Leerink 11/12/20 Chardan Immunovant price target raised to $60 from $45 at Chardan 11/10/20 Piper Sandler Aligos Therapeutics initiated with an Overweight at Piper Sandler NVS Novartis $91.58 / +1.35 (+1.50%) 12/03/20 Argus Novartis price target raised to $112 from $100 at Argus 11/25/20 UBS Novartis price target raised to CHF 99 from CHF 98 at UBS 11/10/20 JPMorgan Novartis price target raised to CHF 85 from CHF 82 at JPMorgan NVO Novo Nordisk $67.82 / +0.62 (+0.92%) 11/16/20 Piper Sandler Piper says 'underwhelming' data from Novo Nordisk a 'big win' for Intercept 11/12/20 JPMorgan Novo Nordisk price target lowered to DKK 470 from DKK 480 at JPMorgan 11/06/20 Morgan Stanley Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley 11/03/20 Societe Generale Novo Nordisk price target raised to DKK 390 from DKK 370 at Societe Generale FMTX Forma Therapeutics $43.53 / -0.26 (-0.59%) 11/19/20 Cantor Fitzgerald Forma Therapeutics initiated with an Overweight at Cantor Fitzgerald 11/18/20 Cantor Fitzgerald Forma Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/08/20 H.C. Wainwright Forma Therapeutics initiated with a Buy at H.C. Wainwright 07/14/20 SVB Leerink Forma Therapeutics initiated with an Outperform at SVB Leerink AZN AstraZeneca $53.71 / +0.93 (+1.76%) 11/30/20 UBS AstraZeneca upgraded to Neutral from Sell at UBS 11/27/20 Citi Citi opens 'positive catalyst watch' on AstraZeneca after vaccine selloff EPZM Epizyme $13.06 / +0.04 (+0.31%) 11/09/20 Barclays Epizyme price target lowered to $18 from $33 at Barclays 10/05/20 Citi Citi highlights Epizyme, Karuna as potential targets after MyoKardia takeover 06/19/20 Citi Epizyme should be bought on any confusion over label, at Citi 06/18/20 Jefferies Jefferies sees broad approval for Epizyme's Taz as 'fundamental positive' FATE Fate Therapeutics $60.68 / +0.29 (+0.48%) 12/02/20 Barclays Fate Therapeutics price target raised to $70 from $60 at Barclays 11/24/20 Truist Fate Therapeutics price target raised to $65 from $40 at Truist 11/09/20 Citi Fate Therapeutics price target raised to $63 from $40 at Citi 11/08/20 Oppenheimer Fate Therapeutics price target raised to $60 from $40 at Oppenheimer DNA Bought by RHHBY $0.00 / + (+0.00%) CRSP Crispr Therapeutics $147.30 / +6.74 (+4.80%) 11/04/20 Roth Capital Crispr Therapeutics data early, but show CTX001's potential, says Roth Capital 11/04/20 Piper Sandler Crispr Therapeutics' CTX001 abstract shows longer durability, says Piper Sandler 11/02/20 Baird Baird starts Editas Medicine with Underperform, $14 price target 10/28/20 Piper Sandler Crispr Therapeutics price target lowered to $107 from $128 at Piper Sandler BMRN BioMarin $79.62 / +0.53 (+0.67%) 11/03/20 Piper Sandler Piper Sandler remains buyer of BioMarin after vosoritide submission 10/22/20 RBC Capital uniQure initiated with an Outperform at RBC Capital 09/10/20 Truist BioMarin price target lowered to $125 from $130 at Truist 08/25/20 JPMorgan Sarepta added to Analyst Focus List, named a Top Idea at JPMorgan BLUE Bluebird Bio $46.91 / -0.13 (-0.28%) 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Bluebird Bio initiated with a Buy at Berenberg 11/06/20 Wedbush Bluebird Bio price target lowered to $73 from $81 at Wedbush BGNE BeiGene $222.79 / +1.61 (+0.73%) 11/19/20 SVB Leerink BeiGene price target raised to $327 from $240 at SVB Leerink 11/09/20 Maxim BeiGene downgraded to Hold from Buy at Maxim 11/09/20 Ladenburg BeiGene downgraded to Neutral from Buy at Ladenburg 11/06/20 Maxim BeiGene downgraded to Hold from Buy at Maxim BAYRY Bayer $0.00 / + (+0.00%) 11/06/20 Morgan Stanley Bayer price target lowered to EUR 67 from EUR 68 at Morgan Stanley 11/05/20 Deutsche Bank Bayer price target lowered to EUR 62 from EUR 64 at Deutsche Bank 11/05/20 JPMorgan Bayer price target lowered to EUR 52 from EUR 77 at JPMorgan 11/04/20 Credit Suisse Bayer price target lowered to EUR 47 from EUR 50 at Credit Suisse ALLO Allogene Therapeutics $33.56 / +1.27 (+3.93%) 11/24/20 BofA Allogene Therapeutics initiated with a Buy at BofA 11/24/20 BofA Allogene Therapeutics initiated with a Buy at BofA 11/04/20 Oppenheimer Allogene weakness after abstract a buying opportunity, says Oppenheimer 11/04/20 Roth Capital Question of safety with Allogene's Allo-CARs may be premature, says Roth Capital AMGN Amgen $229.13 / +2.23 (+0.98%) 11/23/20 Mizuho Cytokinetics regaining omecamtiv could add $3 per share, says Mizuho 11/23/20 H.C. Wainwright Cytokinetics price target lowered to $22 from $43 at H.C. Wainwright 11/23/20 Piper Sandler Piper keeps $25 target on Cytokinetics after Amgen returns omecamtiv mecarbil 11/16/20 Oppenheimer Amgen price target lowered to $274 from $280 at Oppenheimer VRTX TRIL SNY SNDX SGEN SDGR REGN RCKT PFE NVS NVO NEO MOR MNTA KURA KPTI KDMN JNJ JAZZ GILD FMTX FATE EPZM CRSP BMRN BLUE BGNE BAYRY AZN AMGN ALLO ADAP VRTX Vertex Pharmaceuticals $228.24 / +1.58 (+0.70%) 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close 07/30/20 Vertex Pharmaceuticals raises FY20 revenue view to $5.7B-$5.9B from $5.3B-$5.6B 07/30/20 Vertex Pharmaceuticals reports Q2 EPS $2.61, consensus $2.07 TRIL Trillium Therapeutics $17.06 / -0.97 (-5.38%) 11/16/20 Trillium Therapeutics reports 9M EPS ($2.19) vs. (93c) last year 08/12/20 Trillium Therapeutics reports 1H EPS ($1.64) vs. (58c) last year SNY Sanofi $51.01 / +0.97 (+1.94%) 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year 07/29/20 Sanofi reports Q2 business EPS EUR 1.28 vs. EUR 1.18 last year SNDX Syndax $24.59 / +0.5 (+2.08%) 11/02/20 Syndax reports Q3 EPS (46c), consensus (44c) 08/06/20 Syndax reports Q2 EPS (42c), consensus (45c) SGEN Seagen $179.37 / -0.625 (-0.35%) 10/29/20 Seagen reports Q3 EPS $3.50 vs. (55c) last year 07/30/20 Seattle Genetics reports Q2 EPS (12c), consensus (63c) SDGR Schrodinger $66.08 / +1.34 (+2.07%) 11/12/20 Schrodinger reports Q3 EPS 5c, consensus (7c) 08/10/20 Schrodinger reports Q2 EPS (5c), consensus (28c) REGN Regeneron $492.10 / -6.61 (-1.33%) 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 11/04/20 Notable companies reporting before tomorrow's open 08/05/20 Regeneron reports Q2 EPS $7.16, consensus $5.98 RCKT Rocket Pharmaceuticals $32.02 / -1.78 (-5.27%) 11/04/20 Rocket Pharmaceuticals reports Q3 EPS (53c), consensus (46c) 08/05/20 Rocket Pharmaceuticals reports Q2 EPS (45c), consensus (51c) PFE Pfizer $40.36 / +0.26 (+0.65%) 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 10/27/20 Pfizer reports Q3 adjusted EPS 72c, consensus 71c NVS Novartis $91.58 / +1.35 (+1.50%) 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook 10/27/20 Novartis reports Q3 core EPS $1.52, consensus $1.45 07/28/20 Fly Intel: What to watch in large-cap biotech earnings reports NVO Novo Nordisk $67.82 / +0.62 (+0.92%) 10/30/20 Novo Nordisk reports operating profit up 7% at CER in first nine months of 2020 10/08/20 Novo Nordisk boosts 2020 sales growth outlook to 5%-8% from 3%-6% 10/08/20 Novo Nordisk raises sales, operating profit outlook for 2020 08/06/20 Novo Nordisk backs view of 2020 sales growth of 3-6% at CER NEO NeoGenomics $48.00 / +0.13 (+0.27%) 10/27/20 NeoGenomics reports Q3 EPS 4c, consensus 4c 07/28/20 NeoGenomics reports Q2 EPS (6c), consensus (10c) MOR MorphoSys $28.40 / +0.22 (+0.78%) 11/11/20 MorphoSys reports Q3 EBIT (EUR61.7M) vs. (EUR27.0M) last year MNTA Bought by JNJ $52.49 / + (+0.00%) 08/10/20 Momenta reports Q2 EPS (48c), consensus (39c) KURA Kura Oncology $36.79 / +2.78 (+8.17%) 11/05/20 Kura Oncology reports Q3 EPS (42c), consensus (40c) 08/06/20 Kura Oncology reports Q EPS (40c), consensus (42c) KPTI Karyopharm $16.26 / -0.38 (-2.28%) 11/02/20 Karyopharm reports Q3 EPS (73c) with items, consensus (72c) 08/04/20 Karyopharm reports Q2 EPS (63c), consensus (58c) 07/14/20 Karyopharm reports preliminary Q2 XPOVIO sales $18.5M KDMN Kadmon $4.17 / +0.1 (+2.46%) 08/07/20 Kadmon reports Q2 EPS (17c), consensus (14c) JNJ Johnson & Johnson $150.30 / +1.35 (+0.91%) 10/13/20 Johnson & Johnson sees 'robutst, double-digit sales growth' in 2021 10/13/20 Johnson & Johnson sees Q4 sales 'around' 2019 levels, consensus $21.52B 10/13/20 Johnson & Johnson raises FY20 adj. EPS view to $7.95-$8.05 from $7.75-$7.95 10/13/20 Johnson & Johnson reports Q3 adj. EPS $2.20, consensus $1.98 JAZZ Jazz Pharmaceuticals $150.58 / -0.4 (-0.26%) 11/02/20 Jazz Pharma narrows FY20 non-GAAP EPS view to $12.20-$13.00 from $11.90-$13.00 11/02/20 Jazz Pharmaceuticals reports Q3 EPS $4.31, consensus $4.08 08/04/20 Jazz Pharmaceuticals sees FY20 adj. EPS $11.90-$13.00, consensus $11.73 08/04/20 Jazz Pharmaceuticals reports Q2 EPS $2.06, consensus $3.11 GILD Gilead $61.57 / +0.7 (+1.15%) 10/28/20 Gilead sees core business gradually recovering in Q4 and into 1H21 10/28/20 Gilead narrows FY20 adjusted EPS view to $6.25-$6.60 from $6.25-$7.65 10/28/20 Gilead Sciences reports Q3 adjusted EPS $2.11, consensus $1.95 10/28/20 Notable companies reporting after market close FMTX Forma Therapeutics $43.53 / -0.26 (-0.59%) 11/12/20 Forma Therapeutics reports Q3 EPS (67c), consensus (68c) 08/13/20 Forma Therapeutics reports Q2 EPS ($4.58) vs. ($6.03) FATE Fate Therapeutics $60.68 / +0.29 (+0.48%) 11/05/20 Fate Therapeutics reports Q3 EPS (40c), consensus (36c) 08/05/20 Fate Therapeutics reports Q2 EPS (35c), consensus (27c) EPZM Epizyme $13.06 / +0.04 (+0.31%) 11/06/20 Epizyme reports Q3 EPS (55c), consensus (60c) 08/04/20 Epizyme reports Q2 EPS (58c), consensus (61c) CRSP Crispr Therapeutics $147.30 / +6.74 (+4.80%) 10/28/20 Crispr Therapeutics reports Q3 EPS ($1.32), consensus ($1.18) 07/27/20 Crispr Therapeutics reports Q2 EPS ($1.30), consensus (95c) BMRN BioMarin $79.62 / +0.53 (+0.67%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 08/04/20 BioMarin backs FY20 revenue view $1.85B-$1.95B, consensus $1.9B 08/04/20 BioMarin reports Q2 EPS (16c), consensus (11c) BLUE Bluebird Bio $46.91 / -0.13 (-0.28%) 11/04/20 Bluebird Bio reports Q3 EPS ($2.94), consensus ($3.01) 08/05/20 bluebird bio reports Q2 EPS (36c), consensus ($2.60) BGNE BeiGene $222.79 / +1.61 (+0.73%) 11/05/20 BeiGene reports Q3 loss per ADS ($4.81), consensus ($4.12) 08/06/20 BeiGene reports Q2 EPS ($4.31), consensus ($4.77) BAYRY Bayer $0.00 / + (+0.00%) 11/03/20 Bayer confirms FY20 targets, sees core EPS EUR6.70-EUR6.90 11/03/20 Bayer reports Q3 core EPS down 30.2% to EUR0.81 09/30/20 Bayer confirms 2020 adjusted view, sees 2021 core EPS 'slightly' down from 2020 09/30/20 Bayer expects 2021 sales at approximately 2020 levels AZN AstraZeneca $53.71 / +0.93 (+1.76%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER AMGN Amgen $229.13 / +2.23 (+0.98%) 10/28/20 Amgen raises FY20 adjusted EPS view to $15.80-$16.15 from $15.10-$15.75 10/28/20 Amgen reports Q3 adjusted EPS $4.37, consensus $3.80 07/28/20 Amgen raises FY20 adjusted EPS view to $15.10-$15.75 from $14.85-$15.60 ALLO Allogene Therapeutics $33.56 / +1.27 (+3.93%) 11/04/20 Allogene Therapeutics reports Q3 EPS (52c), consensus (54c) 08/05/20 Allogene Therapeutics expects 2020 net losses $260M-$280M 08/05/20 Allogene Therapeutics reports Q2 EPS (53c), consensus (54c) ADAP Adaptimmune $4.46 / -0.04 (-0.89%) 11/05/20 Adaptimmune reports Q3 EPS (4c), consensus (25c) 08/06/20 Adaptimmune reports Q2 EPS (4c), consensus (23c) 02 Dec 11 Sep 13 Aug 07 Aug 01 Jul 19 Jun 09 Jun 02 Jun 02 Jun 27 May 19 May 06 May 30 Apr 30 Apr 04 Mar 06 Feb 23 Jan 22 Jan 12 Dec 11 Dec VRTX SNY REGN PFE NVS MOR JNJ GILD BAYRY AZN AMGN VRTX Vertex Pharmaceuticals $228.24 / +1.58 (+0.70%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says SNY Sanofi $51.01 / +0.97 (+1.94%) 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 10/19/20 Sanofi studying options for older anti-inflammatory products, Bloomberg reports 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports REGN Regeneron $492.10 / -6.61 (-1.33%) 12/04/20 Regeneron must face DOJ suit citing kickbacks, Bloomberg says 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says 10/13/20 FDA flags quality control at Lilly factory making COVID drug, Reuters says 10/08/20 Fauci says 'good chance' Regeneron antibody cocktail aided Trump, Reuters says PFE Pfizer $40.36 / +0.26 (+0.65%) 12/04/20 BioNTech tells Bloomberg 2020 vaccine production on track for 50M doses 12/03/20 Pfizer cuts COVID-19 vaccine rollout target amid supply-chain issues, WSJ says 11/30/20 U.K. set to approve Pfizer-BioNTech COVID vaccine within days, FT reports 11/27/20 Malaysia enter deal with Pfizer to secure COVID-19 vaccine, Bloomberg says NVS Novartis $91.58 / +1.35 (+1.50%) 08/17/20 Novartis patent upheld on Gilenya multiple sclerosis drug, Bloomberg reports 08/06/20 Trump to order government to buy certain drugs from U.S., USA Today says MOR MorphoSys $28.40 / +0.22 (+0.78%) 06/05/20 AstraZeneca cancer drug shows signs of helping in severe COVID-19, Reuters says JNJ Johnson & Johnson $150.30 / +1.35 (+0.91%) 11/20/20 Judge cuts J&J talc verdict to $120M from $325M, Bloomberg reports 11/20/20 New York judge reduces $325M J&J talc verdict, Bloomberg reports GILD Gilead $61.57 / +0.7 (+1.15%) 11/19/20 WHO urges doctors not to use Gilead's remdesivir for coronavirus, Bloomberg says 10/15/20 WHO study says Gilead's remdesivir has little impact on COVID mortality, FT says 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/12/20 Gilead near deal to buy Immunomedics for over $20B, WSJ reports BAYRY Bayer $0.00 / + (+0.00%) 10/27/20 EPA clears use of Bayer's XtendiMax for five years, Reuters reports 10/11/20 Bayer, BASF fighting to keep weedkiller on U.S. farms, WSJ reports 09/15/20 Bayer resolves thousands of U.S. Roundup cases with trial lawyers, Reuters says 09/12/20 Elanco stock well positioned for gains, Barron's says AZN AstraZeneca $53.71 / +0.93 (+1.76%) 12/03/20 AstraZeneca, Oxford give conflicting accounts of COVID-19 trial, Reuters says 11/23/20 Slaoui says severity gap in AstraZeneca COVID trial encouraging, Bloomberg says 11/20/20 Israel close to deal for AstraZeneca's coronavirus vaccine, Reuters says AMGN Amgen $229.13 / +2.23 (+0.98%) 08/24/20 Salesforce, Amgen, Honeywell to join DJIA index, Bloomberg reports 07/06/20 Roche's Genentech loses appeals court bid over Amgen Mvasi, Bloomberg reports 07/06/20 Roche unit loses bid to halt sales of Amgen's Avastin biosimilar, Bloomberg says 07/01/20 Appeals court upholds Amgen patents on Enbrel, Bloomberg reports VRTX TRIL SNY SGEN SDGR REGN PFE NVS NVO MNTA KPTI KDMN JNJ GILD FRLN FMTX EPZM CRSP BMRN BLUE BAYRY AZN AMGN ALLO VRTX Vertex Pharmaceuticals $228.24 / +1.58 (+0.70%) 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 10/15/20 Fly Intel: Pre-market Movers 10/14/20 Fly Intel: After-Hours Movers TRIL Trillium Therapeutics $17.06 / -0.97 (-5.38%) 09/09/20 Fly Intel: After-Hours Movers 09/09/20 Fly Intel: Wall Street's top stories for Wednesday 09/09/20 Fly Intel: Wall Street's top stories at midday 09/08/20 Fly Intel: After-Hours Movers SNY Sanofi $51.01 / +0.97 (+1.94%) 11/21/20 Week in review: How Trump's policies moved stocks 10/06/20 Fly Intel: Wall Street's top stories for Tuesday 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 09/25/20 Fly Intel: Wall Street's top stories for Friday SGEN Seagen $179.37 / -0.625 (-0.35%) 10/29/20 Fly Intel: After-Hours Movers 09/14/20 Fly Intel: Wall Street's top stories for Monday 09/14/20 Fly Intel: Pre-market Movers 07/30/20 Fly Intel: After-Hours Movers SDGR Schrodinger $66.08 / +1.34 (+2.07%) 10/26/20 Fly Insider: Selecta, Netflix among week's notable insider trades 08/10/20 Fly Intel: Wall Street's top stories for Monday 08/10/20 Fly Intel: Wall Street's top stories at midday 08/10/20 Fly Intel: Pre-market Movers REGN Regeneron $492.10 / -6.61 (-1.33%) 11/23/20 Fly Intel: Wall Street's top stories for Monday 11/23/20 Fly Intel: Wall Street's top stories at midday 11/23/20 Fly Intel: Pre-market Movers PFE Pfizer $40.36 / +0.26 (+0.65%) 12/04/20 Fly Intel: Wall Street's top stories for Friday 12/03/20 Fly Intel: Wall Street's top stories for Thursday 12/02/20 Fly Intel: Wall Street's top stories for Wednesday 12/02/20 Fly Intel: Wall Street's top stories at midday NVS Novartis $91.58 / +1.35 (+1.50%) 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday NVO Novo Nordisk $67.82 / +0.62 (+0.92%) 09/30/20 Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication MNTA Bought by JNJ $52.49 / + (+0.00%) 08/19/20 Fly Intel: Wall Street's top stories for Wednesday 08/19/20 Fly Intel: Wall Street's top stories at midday 08/19/20 Fly Intel: Pre-market Movers 06/15/20 Fly Intel: Wall Street's top stories for Monday KPTI Karyopharm $16.26 / -0.38 (-2.28%) 11/02/20 Fly Intel: After-Hours Movers 07/14/20 Fly Intel: Pre-market Movers KDMN Kadmon $4.17 / +0.1 (+2.46%) 09/30/20 Fly Intel: After-Hours Movers JNJ Johnson & Johnson $150.30 / +1.35 (+0.91%) 11/23/20 AstraZeneca reports on COVID vaccine SVB Leerink 'never' sees licensed in U.S. 11/03/20 Fly Intel: Wall Street's top stories for Tuesday 10/30/20 Fly Intel: Wall Street's top stories for Friday GILD Gilead $61.57 / +0.7 (+1.15%) 10/29/20 Fly Intel: Wall Street's top stories for Thursday 10/29/20 Fly Intel: Wall Street's top stories at midday 10/29/20 Fly Intel: Pre-market Movers 10/28/20 Fly Intel: After-Hours Movers FRLN Freeline $16.47 / +0.25 (+1.54%) 08/09/20 Opening Day: Quicken Loans parent raises only $1.8B in IPO FMTX Forma Therapeutics $43.53 / -0.26 (-0.59%) 06/21/20 Opening Day: Royalty Pharma jumps over 50% in largest IPO of 2020 EPZM Epizyme $13.06 / +0.04 (+0.31%) 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday 10/05/20 Cytokinetics, Epizyme highlighted as possible M&A targets after MyoKardia deal 06/29/20 Fly Insider: Epizyme,DraftKings among week's notable insider transactions CRSP Crispr Therapeutics $147.30 / +6.74 (+4.80%) 10/21/20 Fly Intel: Wall Street's top stories for Wednesday 10/21/20 Fly Intel: Pre-market Movers 06/29/20 Fly Intel: After-Hours Movers BMRN BioMarin $79.62 / +0.53 (+0.67%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street BLUE Bluebird Bio $46.91 / -0.13 (-0.28%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street 11/05/20 Fly Intel: Wall Street's top stories for Thursday 11/05/20 Fly Intel: Wall Street's top stories at midday 11/05/20 Microsoft, Verizon upgrades among today's top calls on Wall Street BAYRY Bayer $0.00 / + (+0.00%) 09/30/20 Fly Intel: Wall Street's top stories for Wednesday 09/29/20 Fly Intel: Wall Street's top stories for Tuesday 08/20/20 Fly Intel: Wall Street's top stories for Thursday 06/24/20 Fly Intel: Wall Street's top stories for Wednesday AZN AstraZeneca $53.71 / +0.93 (+1.76%) 11/27/20 Fly Intel: Wall Street's top stories for Friday AMGN Amgen $229.13 / +2.23 (+0.98%) 10/09/20 Fly Intel: Wall Street's top stories for Friday 10/09/20 Fly Intel: Wall Street's top stories at midday 10/09/20 GE reinstatement at Goldman among today's top calls on Wall Street 10/09/20 Fly Intel: Pre-market Movers ALLO Allogene Therapeutics $33.56 / +1.27 (+3.93%) 11/04/20 Fly Intel: Wall Street's top stories for Wednesday 11/04/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Biopharmaceuticals/Biotech 12/06/20 62nd Virtual Annual Meeting of ASH 12/10/20 San Antonio Breast Cancer Virtual Symposium 12/06/20 Syndax - SNDX 12/07/20 Trillium Therapeutics - TRIL 12/07/20 Regeneron - REGN 12/09/20 Crispr Therapeutics - CRSP 01/26/21 Johnson & Johnson - JNJ 12/10/20 Vaccines & Related Biological Products Advisory Committee Meeting 12/15/20 Cardiovascular & Renal Drugs Advisory Committee Meeting 12/15/20 Cardiovascular & Rental Drugs Advisory Committee Meeting 12/16/20 Cardiovascular and Renal Drugs Advisory Committee Meeting 12/30/20 PDUFA Date for TRIKAFTA, SYMDEKO & KALYDECO 01/01/21 PDUFA Date for Xalkori (Crizotinib) - January 2021 02/11/21 PDUFA Date for Evinacumab 03/19/21 PDUFA Date for XPOVIO (Selinexor) (estimated date) 03/27/21 PDUFA Date for Ide-Cel 05/18/21 PDUFA Date for Avalglucosidase Alfa 05/30/21 PDUFA Date fdor Belumosudil 08/20/21 PDUFA Date for Vosoritide VRTX TRIL SDGR REGN PFE NVO MNTA JNJ GILD BMRN AZN AMGN ADAP VRTX Vertex Pharmaceuticals $228.24 / +1.58 (+0.70%) 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th 08/12/20 Early notable gainers among liquid option names on August 12th TRIL Trillium Therapeutics $17.06 / -0.97 (-5.38%) 11/16/20 Largest borrow rate increases among liquid names 07/22/20 Largest borrow rate increases among liquid names SDGR Schrodinger $66.08 / +1.34 (+2.07%) 10/30/20 Largest borrow rate increases among liquid names REGN Regeneron $492.10 / -6.61 (-1.33%) 11/06/20 Regeneron put volume heavy and directionally bearish 10/08/20 Unusually active option classes on open October 8th 10/05/20 Unusually active option classes on open October 5th 07/07/20 Regeneron call volume above normal and directionally bullish PFE Pfizer $40.36 / +0.26 (+0.65%) 12/04/20 Pfizer call volume above normal and directionally bullish 12/04/20 Unusually active option classes on open December 4th 12/04/20 Notable open interest changes for December 4th 12/03/20 Notable open interest changes for December 3rd NVO Novo Nordisk $67.82 / +0.62 (+0.92%) 07/17/20 Novo Nordisk call volume above normal and directionally bullish MNTA Bought by JNJ $52.49 / + (+0.00%) 10/02/20 One new option listing and five option delistings on October 2nd 08/31/20 Momenta put volume heavy and directionally bearish 08/21/20 Momenta call volume above normal and directionally bullish 08/20/20 Unusually active option classes on open August 20th JNJ Johnson & Johnson $150.30 / +1.35 (+0.91%) 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th 09/23/20 Unusually active option classes on open September 23rd 08/24/20 Unusually active option classes on open August 24th GILD Gilead $61.57 / +0.7 (+1.15%) 12/01/20 Gilead call volume above normal and directionally bullish 11/23/20 Gilead put volume heavy and directionally bearish 10/23/20 Early notable gainers among liquid option names on October 23rd 10/23/20 Unusually active option classes on open October 23rd BMRN BioMarin $79.62 / +0.53 (+0.67%) 09/18/20 BioMarin call volume above normal and directionally bullish AZN AstraZeneca $53.71 / +0.93 (+1.76%) 11/27/20 Unusually active option classes on open November 27th 11/23/20 Unusually active option classes on open November 23rd 11/10/20 Largest borrow rate increases among liquid names 11/03/20 Unusually active option classes on open November 3rd AMGN Amgen $229.13 / +2.23 (+0.98%) 08/25/20 Early notable gainers among liquid option names on August 25th 08/25/20 Unusually active option classes on open August 25th 06/18/20 Amgen call volume above normal and directionally bullish ADAP Adaptimmune $4.46 / -0.04 (-0.89%) 06/12/20 Largest borrow rate increases among liquid names 06/11/20 Largest borrow rate increases among liquid names 06/09/20 Largest borrow rate increases among liquid names 06/08/20 Largest borrow rate increases among liquid names
Conference/Events	Zscaler to hold a virtual event » 13:54 12/05/20 12/05 13:54 12/05/20 13:54 ZS Zscaler $180.76 / -4.99 (-2.69%) Virtual Analyst Event… Virtual Analyst Event 2020 will be held on December 9 at 3 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ZS Zscaler $180.76 / -4.99 (-2.69%) 11/12/20 Zscaler appoints Chris Kozup as CMO 09/30/20 Zscaler director sells 20K shares of common stock 09/29/20 JFrog appoints Micheline Nijmeh as chief marketing officer 09/29/20 Zscaler, VMware announce extension of strategic partnership ZS Zscaler $180.76 / -4.99 (-2.69%) 12/03/20 Loop Capital Zscaler price target raised to $215 from $170 at Loop Capital 12/03/20 Credit Suisse Zscaler price target raised to $175 from $160 at Credit Suisse 12/03/20 Wedbush Zscaler price target raised to $185 from $175 at Wedbush 12/03/20 DA Davidson Zscaler price target raised to $185 from $155 at DA Davidson ZS Zscaler $180.76 / -4.99 (-2.69%) 12/03/20 Zscaler raises FY21 EPS view to 37c-38c from 28c-30c, consensus 31c 12/02/20 Zscaler sees Q2 EPS 7c-8c, consensus 7c 12/02/20 Zscaler reports Q1 EPS 14c, consensus 6c 12/02/20 Notable companies reporting after market close ZS Zscaler $180.76 / -4.99 (-2.69%) 09/01/20 Hackers test security of Trump campaign sites ahead of election, Reuters says 06/20/20 Intel, Western Digital among cheap tech stops, Barron's says ZS Zscaler $180.76 / -4.99 (-2.69%) 12/03/20 Fly Intel: Wall Street's top stories for Thursday 12/03/20 Fly Intel: Wall Street's top stories at midday 12/02/20 Fly Intel: After-Hours Movers 09/10/20 Fly Intel: Pre-market Movers 12/07/20 Global TMT Virtual Conference 12/15/20 Semi-Annual Silicon Valley Virtual Tour 12/09/20 Zscaler, Inc. 01/06/21 Zscaler, Inc. ZS Zscaler $180.76 / -4.99 (-2.69%) 12/04/20 Unusually active option classes on open December 4th 12/02/20 Zscaler options imply 13.7% move in share price post-earnings 09/17/20 Zscaler put volume heavy and directionally bearish 09/09/20 Zscaler options imply 17.0% move in share price post-earnings
Conference/Events	DexCom to host virtual investor day » 13:51 12/05/20 12/05 13:51 12/05/20 13:51 DXCM DexCom $348.24 / +3.55 (+1.03%) Virtual Investor Day to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events DXCM DexCom $348.24 / +3.55 (+1.03%) 11/23/20 Tandem Diabetes enters new agreements with DexCom 10/26/20 DexCom announces retirement of Chief Commercial Officer Rick Doubleday 10/07/20 Eli Lilly, DexCom announce joint program for diabetes management 09/24/20 DexCom in five-year diabetes collaboration pact with UVA DXCM DexCom $348.24 / +3.55 (+1.03%) 12/01/20 Baird DexCom weakness creates compelling buying opportunity, says Baird 11/20/20 Piper Sandler DexCom secured national reimbursement in France, says Piper Sandler 10/28/20 Canaccord DexCom price target lowered to $475 from $500 at Canaccord 10/28/20 Raymond James DexCom price target lowered to $438 from $450 at Raymond James DXCM DexCom $348.24 / +3.55 (+1.03%) 10/27/20 Dexcom raises FY20 revenue view to roughly $1.9B from $1.85B, consensus $1.87B 10/27/20 Dexcom reports Q3 adjusted EPS 94c, consensus 64c 10/27/20 Notable companies reporting after market close 10/26/20 DexCom reports Q3 revenue $500.9M, consensus $476.75M DXCM DexCom $348.24 / +3.55 (+1.03%) 10/26/20 Fly Intel: After-Hours Movers 10/02/20 DexCom downgrade, Shake Shack initiation among today's top calls on Wall Street 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades 08/11/20 Medtronic rises following acquisition of insulin pen maker Companion 12/09/20 DexCom, Inc.

On The Fly	Charged: Goldman says buy Tesla, USPS delays decision on NGDV » 08:49 12/05/20 12/05 08:49 12/05/20 08:49 TSLA Tesla $599.00 / +5.95 (+1.00%) , WKHS Workhorse Group $22.07 / -0.585 (-2.58%) , NKLA Nikola $18.86 / -0.14 (-0.74%) , PLUG Plug Power $24.85 / +1 (+4.19%) , XPEV Xpeng $49.42 / -2.065 (-4.01%) , NIO NIO Inc. $43.01 / -2.29 (-5.06%) , BLNK Blink Charging $23.84 / +1.19 (+5.25%) , QSR Restaurant Brands $60.50 / +1.68 (+2.86%) , GM General Motors $44.38 / +0.31 (+0.70%) Welcome to The Fly's… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options XPEV WKHS TSLA QSR PLUG NKLA NIO GM BLNK XPEV Xpeng $49.42 / -2.065 (-4.01%) 12/01/20 Xpeng delivers 4,224 Smart EVs in November 11/25/20 Xpeng falls -8.3% 11/20/20 Xpeng rises 9.8% 11/20/20 Xpeng announces new autonomous driving architecture at Auto Guangzhou WKHS Workhorse Group $22.07 / -0.585 (-2.58%) 12/02/20 USPS says decision on NGDV now planned for Q2 of fiscal 2021 12/02/20 Workhorse sinks 20% after Postal Service again delays vehicle contract 11/23/20 Workhorse Group director sells 99,999 shares of common stock 11/12/20 Electric vehicle makers jump higher after XPeng beats on revenue TSLA Tesla $599.00 / +5.95 (+1.00%) 11/30/20 Tesla jumps 5% to $595.74 after S&P/DJI disclosure regarding its S&P500 addition 11/30/20 Tesla to be added to S&P 500 index at full float-adjusted market capitalization 11/18/20 Tesla CEO says 'only publicly traded stock I own is Tesla' 11/18/20 EU passenger car registrations down 7.8% in October QSR Restaurant Brands $60.50 / +1.68 (+2.86%) 11/19/20 Pershing Square sees improving business fundamentals at Restaurant Brands 10/27/20 Restaurant Brands to modernize over 10,000 Burger King, Tim Hortons drive-thrus 10/22/20 Restaurant Brands' Burger King brand to pilot reusable containers 09/08/20 Regis CEO Hugh Sawyer to retire, Felipe Athayde to succeed PLUG Plug Power $24.85 / +1 (+4.19%) 11/30/20 Plug Power, Gaussin collaborate on hydrogen-powered vehicles 11/24/20 Plug Power raise approx $1B to accelerate green hydrogen network 11/09/20 Plug Power reaffirms 2024 gross billings guidance $1.2B 11/09/20 Plug Power raises 2020 gross billings view $325M-$330M from $310M NKLA Nikola $18.86 / -0.14 (-0.74%) 11/30/20 Nikola turns negative, down 8% after new GM agreement includes no stake 11/30/20 GM to provide Hydrotec fuel system for Nikola's Class 7/8 semi-trucks 11/30/20 Nikola jumps 9% to $30.57 after announcing fuel cell MOU with General Motors 11/30/20 Nikola, GM MOU does not include GM equity stake in Nikola NIO NIO Inc. $43.01 / -2.29 (-5.06%) 12/01/20 NIO Inc. delivers 5,291 vehicles in November, up 109.3% 11/13/20 NIO up 8% to $52.33 after Citron says shares going back to $25 11/02/20 NIO Inc. rises 13.3% GM General Motors $44.38 / +0.31 (+0.70%) 12/01/20 BRP Inc. appoints Katherine Kountze, Ernesto Hernandez to board of directors BLNK Blink Charging $23.84 / +1.19 (+5.25%) 12/03/20 Blink Charging announces charging stations deal with Burger King franchisee 11/24/20 Blink Charging acquires EV charging operator U-Go Stations 11/16/20 Blink Charging introduces Cable Management Solution 11/04/20 Blink Charging expands employee base 30% to support growth TSLA WKHS NKLA PLUG XPEV NIO BLNK QSR GM TSLA Tesla $599.00 / +5.95 (+1.00%) 12/03/20 Fly Intel: Top five analyst upgrades 12/02/20 Goldman Sachs Tesla upgraded to Buy from Neutral at Goldman Sachs 11/27/20 BofA BofA positive on long-term share gains for NIO Inc. after hosting calls 11/18/20 Fly Intel: Top five analyst upgrades WKHS Workhorse Group $22.07 / -0.585 (-2.58%) 12/02/20 Roth Capital USPS delay gives Workhorse competitors more time, says Roth Capital 11/16/20 Workhorse Group initiated with a Buy at Lafferty 11/10/20 Roth Capital Workhorse Group price target lowered to $19 from $27 at Roth Capital 10/26/20 Vertical Group Workhorse Group initiated with a Sell at Vertical Group NKLA Nikola $18.86 / -0.14 (-0.74%) 12/04/20 Deutsche Bank Nikola sees no deterioration in Bosch relationship, says Deutsche Bank 12/01/20 Deutsche Bank GM no longer wants to be tied to Nikola's longer term outlook, says Deutsche 11/30/20 Cowen Nikola deal with GM being mischaracterized, is a positive, says Cowen 11/30/20 JPMorgan Nikola pullback could be a good buying opportunity, says JPMorgan PLUG Plug Power $24.85 / +1 (+4.19%) 11/30/20 Roth Capital Plug Power price target raised to $30 from $22 at Roth Capital 11/12/20 Canaccord Plug Power price target raised to $25 from $13 at Canaccord 11/10/20 Craig-Hallum Plug Power price target raised to $26 from $14 at Craig-Hallum 11/10/20 B. Riley Securities Plug Power price target raised to $24 from $18 at B. Riley Securities XPEV Xpeng $49.42 / -2.065 (-4.01%) 12/02/20 UBS UBS downgrades Xpeng to Neutral, raises price target to $59 12/02/20 UBS Xpeng downgraded to Neutral from Buy at UBS 11/16/20 Citi Xpeng price target raised to $57.71 from $34.70 at Citi 11/09/20 JPMorgan Xpeng price target raised to $43 from $27 at JPMorgan NIO NIO Inc. $43.01 / -2.29 (-5.06%) 12/01/20 Fly Intel: Top five analyst upgrades 12/01/20 Goldman Sachs NIO Inc. upgraded to Neutral from Sell at Goldman Sachs BLNK Blink Charging $23.84 / +1.19 (+5.25%) 08/14/20 Fly Intel: Top five analyst downgrades 08/14/20 H.C. Wainwright Blink Charging downgraded to Neutral from Buy at H.C. Wainwright QSR Restaurant Brands $60.50 / +1.68 (+2.86%) 11/20/20 Stifel Vaccine could aid recovery for urban-exposed restaurant chains, says Stifel 11/03/20 Stephens Restaurant Brands resumed with an Equal Weight at Stephens 10/28/20 Baird Restaurant Brands price target lowered to $60 from $69 at Baird 10/15/20 Fly Intel: Top five analyst downgrades GM General Motors $44.38 / +0.31 (+0.70%) 11/30/20 Wedbush Wedbush keeps Underperform rating on Nikola as revised GM deal disappoints XPEV WKHS TSLA QSR PLUG NKLA NIO GM BLNK XPEV Xpeng $49.42 / -2.065 (-4.01%) 11/12/20 Xpeng sees Q4 revenue RMB 2.2B, up 244% year-over-year 11/12/20 Xpeng reports Q3 EPS (32c), deliveries of 8,578 WKHS Workhorse Group $22.07 / -0.585 (-2.58%) 11/09/20 Workhorse Group reports Q3 revenue $565,000, consensus $1.81M 11/09/20 Workhorse Group reports Q3 revenue $565,000, consensus $1.81M 08/10/20 Workhorse Group reports Q2 revenue $92,000, consensus $270,000 TSLA Tesla $599.00 / +5.95 (+1.00%) 10/21/20 Tesla reports Q3 non-GAAP EPS 76c, consensus 56c 10/21/20 Notable companies reporting after market close 07/22/20 Tesla reports Q2 adjusted EPS 50c, consensus (11c) 07/22/20 Notable companies reporting after market close QSR Restaurant Brands $60.50 / +1.68 (+2.86%) 10/27/20 Restaurant Brands reports Q3 EPS 47c, consensus 56c 10/26/20 Notable companies reporting before tomorrow's open 10/14/20 Restaurant Brands sees Q3 revenue$1.32B-$1.34B consensus $1.15B PLUG Plug Power $24.85 / +1 (+4.19%) 11/09/20 Plug Power reports Q3 EPS (11c), consensus (7c) 08/06/20 Plug Power reaffirms 2020 guidance 08/06/20 Plug Power reaffirms 2024 revenue guidance $1.2B 08/06/20 Plug Power reports Q2 EPS (3c), consensus (10c) NKLA Nikola $18.86 / -0.14 (-0.74%) 11/09/20 Nikola reports Q3 adjusted EPS (16c), consensus (19c) 11/09/20 Notable companies reporting after market close 11/05/20 CNH Industrial reports Q3 adjusted EPS 11c, consensus 2c 08/04/20 Nikola reports Q2 EPS (33c), consensus (13c) NIO NIO Inc. $43.01 / -2.29 (-5.06%) 11/17/20 NIO Inc. sees Q4 revenue $921.8M-$947.9M, consensus $805.66M 11/17/20 NIO Inc. reports Q3 adj. EPS (12c), consensus (17c) 08/11/20 NIO Inc. sees Q3 revenue $572M-$596M, consensus $537.15M 08/11/20 NIO Inc. reports Q2 adj. EPS (15c), consensus (26c) GM General Motors $44.38 / +0.31 (+0.70%) 11/05/20 General Motors reports Q3 adjusted EPS $2.83, consensus $1.38 11/04/20 Notable companies reporting before tomorrow's open 10/13/20 Fly Intel: What to watch in next round of big banks' earnings reports BLNK Blink Charging $23.84 / +1.19 (+5.25%) 11/12/20 Blink Charging reports Q3 EPS (12c), two estimates (9c) 08/13/20 Blink Charging reports Q2 EPS (11c) vs. (9c) last year 17 Nov 31 Aug 27 Aug 12 Aug 11 Jun 14 Feb 06 Dec XPEV WKHS TSLA QSR PLUG NKLA NIO GM BLNK XPEV Xpeng $49.42 / -2.065 (-4.01%) 12/02/20 House approves bill restricting Chinese firms on U.S exchanges, Bloomberg says WKHS Workhorse Group $22.07 / -0.585 (-2.58%) 12/02/20 USPS again delays mail truck replacement contract, Trucks.com reports 10/27/20 Lakewood's Bozza pitches Workhorse short at Robinhood event, Bloomberg says 10/08/20 Workhorse Group fraud 'far worse' than Nikola, says Fuzzy Panda Research TSLA Tesla $599.00 / +5.95 (+1.00%) 12/03/20 Tesla reportedly skips battery testing for Chinese-made Model 3, Inside EVs says 12/01/20 Tesla CEO says would talk over merger if rival carmaker offered, Reuters reports 12/01/20 Tesla CEO says would talk over merger if rival carmaker offered, Reuters reports 12/01/20 Lucid Motors finishes 1st part of construction on Arizona factory, Electrek says QSR Restaurant Brands $60.50 / +1.68 (+2.86%) 07/16/20 Burger King, GM venture criticized on CCTV consumer rights program, Reuters says 07/08/20 Burger King UK head warns of 1,600 potential job losses, BBC reports PLUG Plug Power $24.85 / +1 (+4.19%) 11/21/20 Plug Power soared this year, Walmart/Amazon could benefit too, Barron's says 08/21/20 Plug Power will drop back to $7, Citron Research says 07/25/20 Bubble forming in Hydrogen fuel-cell stocks, Barron's says NKLA Nikola $18.86 / -0.14 (-0.74%) 11/18/20 Nikola tells Bloomberg 'nothing new' to report on General Motors 11/09/20 Nikola may have spent customer deposits, Business Insider reports 10/17/20 Investors should handle EV-SPAC deals with care, Barron's says NIO NIO Inc. $43.01 / -2.29 (-5.06%) 11/13/20 Citron 'pulls the plug' on NIO Inc. long call, sees shares headed back to $25 11/13/20 Citron sees NIO Inc. shares heading back to 'consensus' $25 price target GM General Motors $44.38 / +0.31 (+0.70%) 12/04/20 Nissan joins GM in leaving auto group supporting Trump, Reuters says 12/04/20 Around 17% of Cadillac dealers make choice to exit brand, WSJ reports 11/30/20 General Motors plans to apply for banking charter, WSJ reports 11/23/20 GM no longer supports Trump effort to bar CA emissions rules, Reuters says BLNK Blink Charging $23.84 / +1.19 (+5.25%) 11/23/20 Citron attacks Blink Charging, says shares heading back to $10 11/23/20 Citron calls Blink Charging 'most ridiculous' electric vehicle stock 11/23/20 Blink Charging should trade back to $10, Citron Research says 08/19/20 Mariner issues short report on Blink Charging, sees 90% downside XPEV WKHS TSLA QSR PLUG NKLA NIO BLNK XPEV Xpeng $49.42 / -2.065 (-4.01%) 11/12/20 Fly Intel: Pre-market Movers 11/04/20 Amazon, AMD upgrades among today's top calls on Wall Street WKHS Workhorse Group $22.07 / -0.585 (-2.58%) 11/30/20 Nikola plunges after new GM agreement includes no stake 10/13/20 Workhorse slides after USPS 'punts' decision on $8.1B contract 10/09/20 Workhorse seen as 'best fit' for $8.1B Post Office contract 09/03/20 BofA, JPMorgan upgrades among today's top calls on Wall Street TSLA Tesla $599.00 / +5.95 (+1.00%) 12/03/20 Fly Intel: Wall Street's top stories for Thursday 12/03/20 Fly Intel: Wall Street's top stories at midday 12/03/20 Tesla upgrade, Stitch Fix downgrade among today's top calls on Wall Street 12/02/20 Fly Intel: After-Hours Movers QSR Restaurant Brands $60.50 / +1.68 (+2.86%) 11/03/20 Pinduoduo, Monster Beverage upgrades among today's top calls on Wall Street 10/15/20 ViacomCBS upgrade, Roku downgrade among today's top calls on Wall Street PLUG Plug Power $24.85 / +1 (+4.19%) 11/16/20 Fly Intel: After-Hours Movers 11/02/20 Fly Intel: After-Hours Movers 09/28/20 Fly Intel: Wall Street's top stories at midday 09/03/20 Fly Intel: After-Hours Movers NKLA Nikola $18.86 / -0.14 (-0.74%) 12/01/20 Fly Intel: Wall Street's top stories for Tuesday 12/01/20 Fly Intel: Wall Street's top stories at midday 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday NIO NIO Inc. $43.01 / -2.29 (-5.06%) 12/01/20 Pinterest, FedEx upgrades among today's top calls on Wall Street 11/17/20 Fly Intel: After-Hours Movers BLNK Blink Charging $23.84 / +1.19 (+5.25%) 11/23/20 Fly Intel: Wall Street's top stories for Monday 11/23/20 Fly Intel: Wall Street's top stories at midday 11/13/20 Fly Intel: Pre-market Movers 11/12/20 Fly Intel: After-Hours Movers 12/09/20 Workhorse Group XPEV WKHS TSLA QSR PLUG NKLA NIO GM BLNK XPEV Xpeng $49.42 / -2.065 (-4.01%) 12/01/20 Largest borrow rate increases among liquid names 11/24/20 XPeng call buyer realizes 298% same-day gains 11/19/20 XPeng call volume above normal and directionally bullish 11/12/20 Unusually active option classes on open November 12th WKHS Workhorse Group $22.07 / -0.585 (-2.58%) 11/23/20 Unusually active option classes on open November 23rd 11/20/20 Workhorse Group call volume above normal and directionally bullish 11/17/20 Largest borrow rate increases among liquid names 11/13/20 Largest borrow rate increases among liquid names TSLA Tesla $599.00 / +5.95 (+1.00%) 12/04/20 Notable open interest changes for December 4th 12/01/20 Notable open interest changes for December 1st 11/30/20 Notable open interest changes for November 30th 11/27/20 Notable open interest changes for November 27th QSR Restaurant Brands $60.50 / +1.68 (+2.86%) 08/17/20 Unusually active option classes on open August 17th PLUG Plug Power $24.85 / +1 (+4.19%) 11/27/20 Plug Power call volume above normal and directionally bullish 11/23/20 Plug Power call volume above normal and directionally bullish 11/19/20 Plug Power call volume above normal and directionally bullish 11/16/20 Plug Power call volume above normal and directionally bullish NKLA Nikola $18.86 / -0.14 (-0.74%) 11/24/20 Nikola call volume above normal and directionally bullish 11/19/20 Unusually active option classes on open November 19th 11/18/20 Nikola call volume above normal and directionally bullish 11/13/20 Nikola call volume above normal and directionally bullish NIO NIO Inc. $43.01 / -2.29 (-5.06%) 12/03/20 NIO call buyer realizes 236% same-day gains 12/02/20 Notable open interest changes for December 2nd 11/24/20 Notable open interest changes for November 24th 11/18/20 Notable open interest changes for November 18th GM General Motors $44.38 / +0.31 (+0.70%) 11/05/20 Unusually active option classes on open November 5th 10/21/20 Unusually active option classes on open October 21st 10/20/20 Early notable gainers among liquid option names on October 20th 10/20/20 Unusually active option classes on open October 20th BLNK Blink Charging $23.84 / +1.19 (+5.25%) 11/20/20 Blink Charging call volume above normal and directionally bullish 11/17/20 Unusually active option classes on open November 17th 11/16/20 Blink Charging call volume above normal and directionally bullish 11/12/20 Blink Charging options imply 16.7% move in share price post-earnings
Periodicals	Salesforce paying huge price for Slack, deal might not work, Barron's says » 08:38 12/05/20 12/05 08:38 12/05/20 08:38 CRM Salesforce $225.50 / +4.54 (+2.05%) , WORK Slack Technologies $42.78 / +0.29 (+0.68%) , MSFT Microsoft $214.39 / +0.12 (+0.06%) Salesforce (CRM) has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WORK MSFT CRM WORK Slack Technologies $42.78 / +0.29 (+0.68%) 12/01/20 Salesforce acquires Slack in cash and stock deal worth $27.7B 12/01/20 Salesforce to acquire Slack in cash and stock deal worth $27.7B 11/25/20 Slack Technologies CEO sells 75K shares of common stock 11/25/20 Slack halted for second time, up 16% after report of Salesforce takeover talks MSFT Microsoft $214.39 / +0.12 (+0.06%) 12/03/20 Microsoft acquires eports platform company Smash.gg; terms not disclosed 12/02/20 Digital game spending on Black Friday, Cyber Monday falls 10%, says SuperData 12/02/20 DXC Technology and Microsoft collaborate on DXC MyWorkStyle platform 12/01/20 Microsoft enhances Teams Calling, with CarPlay support CRM Salesforce $225.50 / +4.54 (+2.05%) 12/01/20 Salesforce CEO says fundamental customer experience changes with Slack 12/01/20 Salesforce falls 4% to $231.43 after Q3 earnings, guidance, confirmed Slack deal 12/01/20 Salesforce reports Q3 RPO of $15.3B, up 20% from last year 12/01/20 Salesforce CEO no other major enterprise software company growing at this rate CRM WORK MSFT CRM Salesforce $225.50 / +4.54 (+2.05%) 12/03/20 Wedbush Slack Technologies upgraded to Neutral from Underperform at Wedbush 12/02/20 Needham Salesforce Q3 results were 'mildly disappointing', says Needham 12/02/20 Citi Citi not a fan of Slack acquisition, downgrades Salesforce to Neutral 12/02/20 Raymond James Salesforce price target raised to $280 from $255 at Raymond James WORK Slack Technologies $42.78 / +0.29 (+0.68%) 12/02/20 Cowen Slack Technologies downgraded to Market Perform from Outperform at Cowen MSFT Microsoft $214.39 / +0.12 (+0.06%) 12/04/20 DA Davidson Okta price target raised to $300 from $250 at DA Davidson 12/02/20 Stephens Stephens upgrades ACI Worldwide to Overweight after Starboard urges sale 12/02/20 Stephens Slack Technologies downgraded to Equal Weight from Overweight at Stephens WORK MSFT CRM WORK Slack Technologies $42.78 / +0.29 (+0.68%) 12/01/20 Slack reports Q3 adjusted EPS 1c, consensus (4c) 09/08/20 Slack Technologies sees FY21 EPS (14c) to (13c), consensus (16c) 09/08/20 Slack Technologies sees Q3 EPS (6c) to (5c), consensus (5c) 09/08/20 Slack Technologies reports Q2 EPS 0c, consensus (3c) MSFT Microsoft $214.39 / +0.12 (+0.06%) 10/27/20 Microsoft sees Q2 Productivity and Business Processes revenue $12.75B-$13B 10/27/20 Microsoft reports Q1 EPS $1.82, consensus $1.54 10/27/20 Notable companies reporting after market close 07/22/20 Microsoft reports Q4 EPS $1.46, consensus $1.37 CRM Salesforce $225.50 / +4.54 (+2.05%) 12/01/20 Salesforce initiates FY22 revenue view of $25.45B-$25.55B, consensus $24.5B 12/01/20 Salesforce initiates Q1 revenue view of $5.68B-$5.715B 12/01/20 Salesforce raises FY21 EPS view to $4.62-$4.63 from $3.72-3.74 12/01/20 Salesforce sees Q4 EPS 73c-74c, consensus 86c MSFT CRM MSFT Microsoft $214.39 / +0.12 (+0.06%) 11/30/20 Microsoft to bring Android apps to Windows 10, Windows Central reports 11/25/20 Salesforce has approached Slack with takeover offer, Reuters says 11/24/20 Google has 400 games in development for Stadia, MobileSyrup says 11/20/20 Tech giants threaten to exit Pakistan over censorship law, TechCrunch says CRM Salesforce $225.50 / +4.54 (+2.05%) 11/30/20 Salesforce deal for Slack coming tomorrow at premium, CNBC reports 11/30/20 Salesforce to acquire Slack at premium to current share price, CNBC reports 11/30/20 Salesforce acquisition of Slack to be announced tomorrow, CNBC reports 11/25/20 Oracle viewed as possible rival suitor for Slack, New York Post says WORK MSFT CRM WORK Slack Technologies $42.78 / +0.29 (+0.68%) 12/02/20 Salesforce slips as Wall Street digests 'fairly outlandish' price paid for Slack MSFT Microsoft $214.39 / +0.12 (+0.06%) 12/01/20 Game On: PS5 breaks U.K. launch sales record 12/01/20 Fly Intel: What to watch in Salesforce's earnings report 11/24/20 Game On: KeyBanc concerned about lack of 'Call of Duty' sales data CRM Salesforce $225.50 / +4.54 (+2.05%) 12/02/20 Fly Intel: Wall Street's top stories for Wednesday 12/02/20 #SocialStocks: Analysts unimpressed with Slack deal 12/02/20 Fly Intel: What to watch in Snowflake earnings report 12/02/20 Fly Intel: Wall Street's top stories at midday 12/07/20 Global TMT Virtual Conference 12/14/20 Salesforce Virtual Summit Around Dreamforce 2020 12/15/20 Semi-Annual Silicon Valley Virtual Tour 01/14/21 2021 Virtual Software Bus Tour 12/09/20 Slack Technologies - WORK 12/08/20 Salesforce.com, Inc. WORK MSFT CRM WORK Slack Technologies $42.78 / +0.29 (+0.68%) 12/01/20 Notable open interest changes for December 1st 11/27/20 Notable open interest changes for November 27th 11/27/20 Unusual call flow in option market yesterday MSFT Microsoft $214.39 / +0.12 (+0.06%) 11/11/20 Notable open interest changes for November 11th 10/28/20 Notable open interest changes for October 28th 10/27/20 Notable open interest changes for October 27th 10/27/20 Microsoft call buyer realizes 16% same-day gains CRM Salesforce $225.50 / +4.54 (+2.05%) 12/03/20 Notable open interest changes for December 3rd 12/01/20 Salesforce options imply 9.1% move in share price post-earnings 11/27/20 Unusually active option classes on open November 27th 08/27/20 Notable open interest changes for August 27th
Downgrade	Canadian Western Bank downgraded to Market Perform at BMO Capital » 08:37 12/05/20 12/05 08:37 12/05/20 08:37 CBWBF Canadian Western Bank $0.00 / + (+0.00%) BMO Capital analyst… BMO Capital analyst Sohrab Movahedi downgraded Canadian Western Bank to Market Perform from Outperform with a price target of C$31, down from C$36. The analyst believes the company's elevated expenses in fiscal 2021 warrants a downgrade. ShowHide Related Items >><< Street Research CBWBF Canadian Western Bank $0.00 / + (+0.00%) 11/23/20 Scotiabank Canadian Western Bank price target raised to C$33 from C$29 at Scotiabank 11/18/20 National Bank Canadian Western Bank price target raised to C$30 from C$28 at National Bank 10/28/20 Raymond James Canadian Western Bank initiated with an Outperform at Raymond James 09/09/20 Barclays Canadian Western Bank price target raised to C$30 from C$27 at Barclays
Periodicals	DoorDash has been a COVID winner, IPO might not be, Barron's says » 08:31 12/05/20 12/05 08:31 12/05/20 08:31 DASH DoorDash $0.00 / + (+0.00%) DoorDash is going public… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Syndicate Periodicals On The Fly DASH DoorDash $0.00 / + (+0.00%) 12/01/20 Fly Intel: Top five analyst initiations 12/01/20 Loop Capital Uber price target raised to $59 from $40 at Loop Capital 12/01/20 DA Davidson DoorDash initiated with a Buy at DA Davidson 07/08/20 Wedbush Postmates stronger fit for Uber, less market share than GrubHub, says Wedbush 09 Dec DASH DoorDash $0.00 / + (+0.00%) 11/30/20 DoorDash IPO expected to price on Dec. 8th and start trading Dec. 9th, DJ says 09/02/20 Dating app Bumble planning IPO at $6B-plus value, Bloomberg reports DASH DoorDash $0.00 / + (+0.00%) 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO 08/13/20 Micron downgrade, Estee Lauder upgrade among today's top calls on Wall Street
Periodicals	Airbnb's IPO will be hot, stock worth the price, Barron's says » 08:20 12/05/20 12/05 08:20 12/05/20 08:20 ABNB Airbnb $0.00 / + (+0.00%) Airbnb could be one of… Airbnb could be one of the hottest initial public offerings of the year, Andrew Bary writes in this week's edition of Barron's. With its asset-light business model and global presence, the company is poised to benefit from a rebound in travel, the author notes. While the proposed market value of Airbnb - around $30B at the top of the proposed pricing range of $44-$50 a share - isn't cheap, valuation looks reasonable given the company's market position, scarcity value, brand power, and global opportunity at a time when investors regularly value exciting growth companies at considerably more than 10 times annual sales, Bary adds. Reference Link ShowHide Related Items >><< Company News Street Research Syndicate Periodicals On The Fly ABNB Airbnb $0.00 / + (+0.00%) 11/17/20 Airbnb sees bigger Q4 decline in Nights/Experiences Booked, Gross Booking Value ABNB Airbnb $0.00 / + (+0.00%) 12/02/20 Fly Intel: Top five analyst initiations 12/02/20 Atlantic Equities Atlantic Equities starts Airbnb with Overweight, $75 price target 12/02/20 Atlantic Equities Airbnb initiated with an Overweight at Atlantic Equities 10 Dec ABNB Airbnb $0.00 / + (+0.00%) 12/01/20 Airbnb targets $34.8B valuation in IPO, Reuters reports 11/20/20 Tech giants threaten to exit Pakistan over censorship law, TechCrunch says 06/09/20 Airbnb resumes internal IPO talks, Axios reports ABNB Airbnb $0.00 / + (+0.00%) 12/01/20 Fly Intel: Wall Street's top stories for Tuesday

On The Fly	Week in review: How Trump's policies moved stocks » 08:08 12/05/20 12/05 08:08 12/05/20 08:08 TWTR Twitter $47.74 / -0.06 (-0.13%) , FB Facebook $279.65 / -2.04 (-0.72%) , AAPL Apple $122.23 / -0.71 (-0.58%) , HNHPF Hon Hai Precision $0.00 / + (+0.00%) Catch up on the top… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options TWTR HNHPF FB AAPL TWTR Twitter $47.74 / -0.06 (-0.13%) 12/02/20 Trump threatens veto of Defense Act without action on Section 230 11/24/20 Twitter announces plans to 'revamp' verification process 11/17/20 Twitter rolls out disappearing tweets called Fleets 11/16/20 Einhorn's Greenlight buys Twitter, exits Whirlpool in Q3 HNHPF Hon Hai Precision $0.00 / + (+0.00%) 06/18/20 Medtronic, Foxconn partner to increase ventilator production FB Facebook $279.65 / -2.04 (-0.72%) 12/03/20 Facebook to remove false claims about COVID-19 vaccines 12/02/20 Facebook director sells 13.1K shares of common stock 12/02/20 Facebook's cryptocurrency project rebrands as Diem AAPL Apple $122.23 / -0.71 (-0.58%) 12/01/20 Amazon Web Services announces EC2 Mac instances for EC2 11/29/20 Fly Intel: Top five weekend stock stories 11/23/20 Apple pushes deadline for requiring in-app purchases for online event apps 11/19/20 Nvidia, Epic Games to enable 'touch-friendly' version of Fortnite for Apple iOS TWTR FB AAPL HNHPF TWTR Twitter $47.74 / -0.06 (-0.13%) 11/16/20 BofA Comcast, Eaton, Nice & Twitter added to US 1 List at BofA 11/02/20 Citi Twitter price target raised to $42 from $36 at Citi 10/30/20 Oppenheimer Twitter price target raised to $55 from $46 at Oppenheimer 10/30/20 Deutsche Bank Twitter price target raised to $64 from $56 at Deutsche Bank FB Facebook $279.65 / -2.04 (-0.72%) 11/27/20 Truist Amazon to claim 42c of every e-commerce dollar spent, says Truist 11/27/20 MKM Partners Facebook, Google may also be interested in Slack, says MKM Partners 10/30/20 Raymond James Facebook price target raised to $320 from $280 at Raymond James 10/30/20 Canaccord Facebook price target raised to $330 from $315 at Canaccord AAPL Apple $122.23 / -0.71 (-0.58%) 12/04/20 BWS Financial AXT Inc. news on Osram could imply win at Apple, says BWS Financial 12/01/20 Raymond James Apple Store 'not a new channel' for Arlo Technologies, says Raymond James 12/01/20 Credit Suisse Modest uptick in iPhone 12 Pro waits, Pro Max remains stable, says Credit Suisse 11/30/20 Fly Intel: Top five analyst upgrades HNHPF Hon Hai Precision $0.00 / + (+0.00%) 02/24/20 Morgan Stanley Hon Hai Precision upgraded to Overweight from Equal Weight at Morgan Stanley TWTR FB AAPL TWTR Twitter $47.74 / -0.06 (-0.13%) 10/29/20 Twitter reports Q3 adjusted EPS 19c, consensus 6c 10/29/20 Notable companies reporting after market close 07/23/20 Twitter reports Q2 adjusted EPS (16c), consensus 0c 07/22/20 Notable companies reporting before tomorrow's open FB Facebook $279.65 / -2.04 (-0.72%) 10/29/20 Facebook sees Q4 ad revenue growth rate higher than Q3 10/29/20 Facebook reports Q3 EPS $2.71, consensus $1.91 07/30/20 Facebook reports Q2 EPS $1.80, consensus $1.39 AAPL Apple $122.23 / -0.71 (-0.58%) 10/29/20 Apple says Q4 results were ahead of expectations 10/29/20 Apple reports Q4 Services revenue $14.55B vs. $12.51B last year 10/29/20 Apple reports Q4 iPhone revenue $24.44B vs. $33.36B last year 10/29/20 Apple reports Q4 EPS 73c, consensus 70c TWTR HNHPF FB AAPL TWTR Twitter $47.74 / -0.06 (-0.13%) 11/20/20 Tech giants threaten to exit Pakistan over censorship law, TechCrunch says 11/16/20 Twitter appoints 'famed' hacker 'Mudge' to top security spot, Reuters says 11/04/20 Twitter disables fake AP accounts making false U.S. election calls, Reuters says 11/04/20 Turkey fines Facebook, Twitter for breaching new content law, WSJ says HNHPF Hon Hai Precision $0.00 / + (+0.00%) 12/03/20 Foxconn, Quanta eyeing opportunities in O-RAN hardware supply, DigiTimes says 11/30/20 Apple asks Foxconn to move some production to Vietnam, Reuters reports 11/17/20 iPhone 12 supply chain makers taking measures to boost output, DigiTimes says 11/16/20 Foxconn expanding production outside China, DigiTimes reports FB Facebook $279.65 / -2.04 (-0.72%) 12/03/20 DOJ says Facebook 'improperly' held jobs for H-1B workers, WSJ reports 12/02/20 Group of states to file suit against Facebook on antitrust grounds, Reuters says 12/02/20 Facebook looks to help Biden administration with vaccine response, BI reports 12/02/20 SoftBank to abandon large U.S. equity options trades, FT reports AAPL Apple $122.23 / -0.71 (-0.58%) 12/04/20 Dutch antitrust probe into payment apps targeting Apple Pay, Bloomberg says 12/02/20 Judge in Google case dismisses DOJ's protective order request, Reuters says 12/02/20 TSMC plans to roll out enhanced 3nm process in 2023, DigiTimes reports 12/02/20 Roku hires Apple's chief Siri architect Brian Pinkerton, Bloomberg reports TWTR FB AAPL TWTR Twitter $47.74 / -0.06 (-0.13%) 11/25/20 #SocialStocks: Social media platforms bump heads with foreign governments 11/18/20 #SocialStocks: Facebook, Twitter CEOs testify before Senate committee 11/04/20 #SocialStocks: Twitter and Facebook closely monitor election content 11/02/20 Fly Intel: After-Hours Movers FB Facebook $279.65 / -2.04 (-0.72%) 12/04/20 The Intersection: Crypto and Wall Street This Week 12/02/20 #SocialStocks: Analysts unimpressed with Slack deal 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday AAPL Apple $122.23 / -0.71 (-0.58%) 11/30/20 Apple upgrade, Slack downgrade among today's top calls on Wall Street 11/24/20 Game On: KeyBanc concerned about lack of 'Call of Duty' sales data 02/25/21 Twitter, Inc. TWTR FB AAPL TWTR Twitter $47.74 / -0.06 (-0.13%) 10/30/20 Notable open interest changes for October 30th 10/30/20 Twitter call buyer realizes 67% same-day gains 10/29/20 Twitter options imply 21.7% move in share price post-earnings 10/23/20 Twitter call buyer realizes 25% same-day gains FB Facebook $279.65 / -2.04 (-0.72%) 10/22/20 Facebook put buyer realizes 41% same-day gains 10/21/20 Early notable gainers among liquid option names on October 21st 10/21/20 Unusually active option classes on open October 21st AAPL Apple $122.23 / -0.71 (-0.58%) 12/04/20 Notable open interest changes for December 4th 12/03/20 Notable open interest changes for December 3rd 12/02/20 Notable open interest changes for December 2nd 12/01/20 Notable open interest changes for December 1st
Conference/Events	Lowe's to host virtual analyst day » 21:00 12/04/20 12/04 21:00 12/04/20 21:00 LOW Lowe's $150.00 / -1.845 (-1.22%) Virtual Analyst Day to be… Virtual Analyst Day to be held on December 9 at 8 am. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LOW Lowe's $150.00 / -1.845 (-1.22%) 11/19/20 Pershing believes Lowe's has potential to appreciate substantially over time 11/19/20 Pershing Square: Lowe's doing 'phenomenally well' 11/18/20 Lowe's falls -6.1% 11/18/20 Lowe's expects Pro business to accelerate post-COVID-19 pandemic LOW Lowe's $150.00 / -1.845 (-1.22%) 12/04/20 Morgan Stanley Lowe's, Home Depot price targets raised at Morgan Stanley 11/18/20 Baird Lowe's Q3 comps 'robust', Q4 EBIT margin guidance 'flattish', says Baird 11/18/20 Wells Fargo Lowe's long-term transformation making progress, says Wells Fargo 11/18/20 Baird Lowe's pullback likely a buying opportunity, says Baird LOW Lowe's $150.00 / -1.845 (-1.22%) 11/18/20 Lowe's sees Q4 adj. EPS $1.10-$1.20, consensus $1.16 11/18/20 Lowe's reports Q3 adj. EPS $1.98, consensus $1.99 11/17/20 Notable companies reporting before tomorrow's open LOW Lowe's $150.00 / -1.845 (-1.22%) 11/09/20 Lowe's in talks to acquire HD Supply, Bloomberg says 07/17/20 NFL's brand partnerships to play big safety role for 2020 season, CNBC says LOW Lowe's $150.00 / -1.845 (-1.22%) 11/18/20 Fly Intel: Wall Street's top stories for Wednesday 11/18/20 Fly Intel: Wall Street's top stories at midday 11/18/20 Fly Intel: Pre-market Movers 11/16/20 Fly Intel: What to watch in Home Depot, Lowe's earnings reports 12/09/20 Lowe's Companies Inc. LOW Lowe's $150.00 / -1.845 (-1.22%) 11/18/20 Unusually active option classes on open November 18th 08/26/20 Lowe's call volume above normal and directionally bullish 06/17/20 Early notable gainers among liquid option names on June 17th
Hot Stocks	Crowdstrike CEO: Target is a great partner for us » 18:35 12/04/20 12/04 18:35 12/04/20 18:35 CRWD Crowdstrike $167.35 / +6.15 (+3.82%) In an interview on… In an interview on CNBC's Mad Money, George Kurtz said, "Target is a marquee name and we are proud to have them as a customer." Crowdstrike protects many of the large pharmaceutical companies, Kurtz noted. COVID-19 has prompted a number of malware/phishing attacks, and the threat environment continues to get worse, he said. The trend of companies moving to the cloud is sustainable and Crowdstrike is well-positioned to take advantage of that, Kurtz added. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options CRWD Crowdstrike $167.35 / +6.15 (+3.82%) 12/03/20 Crowdstrike participating in launch of Professional Services in AWS Marketplace 12/02/20 Crowdstrike jumps 9% to $155 per share after Q3 earnings beat and FY21 guidance 11/25/20 Crowdstrike Chairman Watzinger sells $4.4M in company shares 11/16/20 Tiger Global adds Snowflake, GSX and BigCommerce during Q3 CRWD Crowdstrike $167.35 / +6.15 (+3.82%) 12/04/20 Credit Suisse Crowdstrike price target raised to $150 from $125 at Credit Suisse 12/04/20 BTIG Crowdstrike price target raised to $190 from $164 at BTIG 12/03/20 FBN Securities Crowdstrike price target raised to $200 from $150 at FBN Securities 12/03/20 DA Davidson Crowdstrike price target raised to $185 from $160 at DA Davidson CRWD Crowdstrike $167.35 / +6.15 (+3.82%) 12/02/20 Crowdstrike sees FY21 EPS 21c-22c, consensus 6c 12/02/20 Crowdstrike sees Q4 EPS 8c-9c, consensus 1c 12/02/20 Crowdstrike reports Q3 EPS 8c, consensus 0c 12/02/20 Notable companies reporting after market close 26 Jun 07 Jan 09 Dec CRWD Crowdstrike $167.35 / +6.15 (+3.82%) 08/15/20 Cisco earnings showing tech stock not immune to COVID, Barron's says 06/20/20 Intel, Western Digital among cheap tech stops, Barron's says CRWD Crowdstrike $167.35 / +6.15 (+3.82%) 12/02/20 Fly Intel: After-Hours Movers 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street 10/14/20 Fly Intel: After-Hours Movers 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades 12/07/20 Global TMT Virtual Conference CRWD Crowdstrike $167.35 / +6.15 (+3.82%) 12/02/20 CrowdStrike Holdings options imply 15.8% move in share price post-earnings 10/02/20 Unusual call flow in option market yesterday 10/01/20 CrowdStrike calls see early buying as stock lifts 5% 09/02/20 CrowdStrike Holdings options imply 30.7% move in share price post-earnings
Conference/Events	Mirum Pharmaceuticals to host virtual investor day » 18:13 12/04/20 12/04 18:13 12/04/20 18:13 MIRM Mirum Pharmaceuticals $23.90 / +0.04 (+0.17%) Virtual Investor Day to… Virtual Investor Day to be held on December 9 at 11 am. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events MIRM Mirum Pharmaceuticals $23.90 / +0.04 (+0.17%) 11/30/20 Mirum Pharmaceuticals announces maralixibat MAA accepted for review by EMA 11/15/20 Mirum Pharmaceuticals announces data from ITCH, IMAGINE II studies 11/05/20 Mirum broadens EAP for maralixibat to treat cholestatic pruritus 10/15/20 Mirum Pharmaceuticals partnering with Eversana for U.S. launch of maralixibat MIRM Mirum Pharmaceuticals $23.90 / +0.04 (+0.17%) 11/30/20 Piper Sandler Mirum continues to deliver on milestones, says Piper Sandler 11/13/20 Raymond James Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James 10/15/20 Piper Sandler Mirum putting cards in place for maralixibat rollout, says Piper Sandler 09/28/20 Piper Sandler Mirum opportunity in Alagille syndrome higher than expected, says Piper Sandler MIRM Mirum Pharmaceuticals $23.90 / +0.04 (+0.17%) 11/12/20 Mirum Pharmaceuticals reports Q3 EPS (86c), consensus (97c) 08/06/20 Mirum Pharmaceuticals reports Q2 EPS (93c), consensus (87c) 09 Jan MIRM Mirum Pharmaceuticals $23.90 / +0.04 (+0.17%) 09/30/20 Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication 12/09/20 Mirum Pharmaceuticals, Inc.
Conference/Events	Arcutis Biotherapeutics to host virtual investor day » 18:11 12/04/20 12/04 18:11 12/04/20 18:11 ARQT Arcutis Biotherapeutics $26.00 / -0.57 (-2.15%) Virtual Investor Day to… Virtual Investor Day to be held on December 9 at 11 am. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events ARQT Arcutis Biotherapeutics $26.00 / -0.57 (-2.15%) 12/01/20 Arcutis Biotherapeutics presents data on roflumilast cream study for psoriasis 11/23/20 Arcutis Biotherapeutics announces data from Phase 2b study of ARQ-154 11/02/20 Arcutis Biotherapeutics presents data from Phase 2 studies of ARQ-151 10/26/20 Arcutis Biotherapeutics completes enrollment in Phase 1/2b study of ARQ-252 ARQT Arcutis Biotherapeutics $26.00 / -0.57 (-2.15%) 11/09/20 Goldman Sachs Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs 10/08/20 Truist Arcutis Biotherapeutics initiated with a Buy at Truist 10/08/20 Truist Arcutis Biotherapeutics initiated with a Buy at Truist 03/20/20 Cantor Fitzgerald Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald ARQT Arcutis Biotherapeutics $26.00 / -0.57 (-2.15%) 11/05/20 Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c) 08/11/20 Arcutis Biotherapeutics reports Q2 EPS (94c), consensus (84c) 02 Oct 31 Jan ARQT Arcutis Biotherapeutics $26.00 / -0.57 (-2.15%) 10/12/20 Fly Insider: Element Solutions, Sunrun among week's notable insider trades 09/29/20 Fly Intel: After-Hours Movers 06/22/20 Meet Arcutis Biotherapeutics: A Fly exclusive interview with CEO Frank Watanabe 12/09/20 Arcutis Biotherapeutics, Inc.

Events

Earnings calls, analyst events, roadshows and more

CBIO ...
Tomorrow at 00:00

62nd Virtual Annual Meeting of ASH Conferences

Virtual Meeting
SNDX
Tomorrow at 14:00

Syndax - SNDX Conference Calls
APTO
Tomorrow at 17:00

Aptose Biosciences - APTO Conference Calls
Tomorrow at 17:00

Biotechnology Industry Meetings
HTHT
Tomorrow at 20:00

Huazhu Group - HTHT Conference Calls
BAND
2020-12-07 at 00:00

Bandwidth - BAND Conference Calls
ETSY
2020-12-07 at 00:00

Etsy - ETSY Conference Calls
HRI
2020-12-07 at 00:00

Herc Holdings - HRI Conference Calls
2020-12-07 at 00:00

2020 Wells Fargo Virtual E-Commerce Expert Day Conferences

Virtual Conference
ATVI ...
2020-12-07 at 00:00

Global TMT Virtual Conference Conferences

Virtual Conference

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	NDLS X NDLS Noodles & Company Block Trade Managers: Morgan Stanley Priced at: $7.65 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AQUA X AQUA Evoqua Water Secondary Managers: Citi Priced at: $25.15 12M Shares ELAN X ELAN Elanco Secondary Managers: BofA, Goldman Sachs & Credit Suisse Priced at: $30.25 54.5M Shares POWW X POWW AMMO Secondary Managers: Alexander Capital & Kingswood Priced at: $2.10 8.564M Shares NOVA X NOVA Sunnova Energy Spot Secondary Managers: Goldman Sachs, BofA, JPMorgan & Credit Suisse Priced at: $37.00 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	CVNA X CVNA Carvana Block Trade Managers: Citi Priced at: $241.10 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial COGT X COGT Cogent Biosciences Secondary Managers: Jefferies & Piper Sandler, Wedbush, LIFC, Ladenburg Priced at: $9.75 10.256M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDGS X MDGS Medigus Secondary Managers: Aegis Priced at: $1.83 7.098M Shares NTLA X NTLA Intellia Therapeutics Secondary Managers: Goldman Sachs, Jefferies & SVB Leerink Priced at: $36.50 4.795M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ZI X ZI ZoomInfo Secondary Managers: JPMorgan & Morgan Stanley Priced at: $45.00 12.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ALNA X ALNA Allena Pharmaceuticals Spot Secondary Managers: H.C. Wainwright Priced at: $1.25 10.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BGNE X BGNE BeiGene Spot Secondary Managers: Goldman Sachs Priced at: $225 1.512M Shares ED X ED Consolidated Edison Spot Secondary Managers: BofA Priced at: $76.85 7.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FCEL X FCEL FuelCell Spot Secondary Managers: JPMorgan Priced at: $6.50 34.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JBLU X JBLU JetBlue Spot Secondary Managers: Morgan Stanley, Goldman Sachs, Barclays & BNP Paribas Priced at: $14.40 36.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RETA X RETA Reata Pharmaceuticals Spot Secondary Managers: Barclays & Goldman Sachs Priced at: $140.85 2M Shares REXR X REXR Rexford Industrial Spot Secondary Managers: JPMorgan & Goldman Sachs Priced at: $47.40 6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Spot Secondary Managers: Goldman Sachs & BofA Priced at: $61.90 6M Shares
Wed	KNTE X KNTE Kinnate Biopharma IPO Managers: Goldman Sachs, SVB Leerink & Piper Sandler, Wedbush Priced at: $20.00 12M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACHV X ACHV Achieve Life Sciences Secondary Managers: Lake Street, Maxim Priced at: $7.00 2.15M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ARRY X ARRY Array Technologies Secondary Managers: Goldman Sachs & JPMorgan, Guggenheim Priced at: $35.00 31.875M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FOUR X FOUR Shift4 Payments Secondary Managers: Goldman Sachs, Credit Suisse & Citi Priced at: $55.50 8M Shares OM X OM Outset Medical Secondary Managers: BofA, Morgan Stanley, GSCO LEER & Stifel Priced at: $53.00 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial OSH X OSH Oak Street Health Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley, William Blair & Piper Sandler Priced at: $46.00 5.63M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PROG X PROG Progenity Secondary Managers: Piper Sandler & Wells Fargo, BTIG Priced at: $3.27 7.645M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TWST X TWST Twist Bioscience Secondary Managers: JPMorgan, Goldman Sachs, Cowen & Evercore ISI, Baird Priced at: $110.00 2.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial XP X XP XP Inc. Secondary Managers: XP, Itau BBA, Morgan Stanley & JPMorgan Priced at: $39.00 31.655M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDXS X CDXS Codexis Spot Secondary Managers: Jefferies, Cowen & Stifel, Craig-Hallum, Stephens Priced at: $17.50 4.289M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DADA X DADA Dada Nexus Spot Secondary Managers: Goldman Sachs, BofA, Jefferies, Haitong & KeyBanc Priced at: $50.00 9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GLNG X GLNG Golar LNG Spot Secondary Managers: Citi, Clarksons Platou & DNB Markets, Arctic Securities Priced at: $8.75 11M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VERI X VERI Veritone Spot Secondary Managers: Stifel, JMP Securities, Roth Capital Priced at: $18.50 3M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	DCBO X DCBO Docebo IPO Managers: Morgan Stanley, Goldman Sachs & Canaccord Priced at: $48.00 3M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SBTX X SBTX Silverback Therapeutics IPO Managers: Goldman Sachs, SVB Leerink & Stifel, H.C. Wainwright Priced at: $21.00 11.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SEER X SEER Seer IPO Managers: JPMorgan, Morgan Stanley, BofA & Cowen Priced at: $19.00 9.21M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SGTX X SGTX Sigilon Therapeutics IPO Managers: Morgan Stanley, Jefferies, Barclays & Canaccord Priced at: $18.00 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial YQ X YQ 17 Entertainment IPO Managers: Goldman Sachs, Morgan Stanley & BofA Priced at: $10.50 27.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNR X BNR Burning Rock Biotech Secondary Managers: Morgan Stanley, BofA & Cowen Priced at: $25.75 2.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMBM X CMBM Cambium Networks Secondary Managers: JPMorgan, Jefferies, Raymond James Priced at: $28.00 2.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LI X LI Li Auto Secondary Managers: Goldman Sachs, UBS & CICC Priced at: $29.00 47M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ONDS X ONDS Ondas Secondary Managers: Oppenheimer, National Securities, Northland, Spartan Priced at: $6.00 5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Fly Intel: Top five analyst downgrades

TODAY'S FREE FLY STORIES

Get Full Fly Access